

## Histology-informed liver diffusion MRI: biophysical model design and demonstration in cancer immunotherapy

Francesco Grussu<sup>1\*</sup>, Kinga Bernatowicz<sup>1</sup>, Marco Palombo<sup>2,3</sup>, Irene Casanova-Salas<sup>1</sup>, Ignasi Barba<sup>1,4</sup>, Sara Simonetti<sup>1</sup>, Garazi Serna<sup>1</sup>, Athanasios Grigoriou<sup>1,5</sup>, Anna Voronova<sup>1,5</sup>, Valezka Garay<sup>6</sup>, Juan Francisco Corral<sup>7,8</sup>, Marta Vidorreta<sup>9</sup>, Pablo García-Polo García<sup>10</sup>, Xavier Merino<sup>7,8</sup>, Richard Mast<sup>7,8</sup>, Núria Roson<sup>7,8</sup>, Manuel Escobar<sup>7,8</sup>, Maria Vieito<sup>11</sup>, Rodrigo Toledo<sup>1</sup>, Paolo Nuciforo<sup>1</sup>, Joaquin Mateo<sup>11</sup>, Elena Garralda<sup>11</sup>, Raquel Perez-Lopez<sup>1\*</sup>

\*Joint corresponding authors. Email: [fgrussu@vhio.net](mailto:fgrussu@vhio.net) (F.G.), [rperez@vhio.net](mailto:rperez@vhio.net) (R.P.L.)

<sup>1</sup> Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Spain <sup>2</sup> Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, United Kingdom <sup>3</sup> School of Computer Science and Informatics, Cardiff University, Cardiff, UK <sup>4</sup> University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain <sup>5</sup> Department of Biomedicine, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain <sup>6</sup> PET/MR Unit, CETIR-ASCIREs, Barcelona, Spain <sup>7</sup> Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain <sup>8</sup> Institut de Diagnòstic per la Imatge (IDI), Barcelona, Spain <sup>9</sup> Siemens Healthineers, Madrid, Spain <sup>10</sup> GE HealthCare, Madrid, Spain <sup>11</sup> Medical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Spain

### Abstract

Innovative diffusion Magnetic Resonance Imaging (dMRI) models enable *in vivo* mapping of biologically meaningful properties such as cell size, potential biomarkers in cancer. However, while cancers frequently spread to the liver, models tailored for liver applications and easy to deploy in the clinic are still sought. We tackle this unmet need by delivering a practical and clinically viable liver dMRI modelling framework. Through direct comparison of candidate dMRI approaches in mouse and cancer patients' data, we select a model of intra-cellular diffusion fitted to highly diffusion-weighted images, as it provides the strongest radiological-histological correlates. We demonstrate the potential application of the proposed model in cancer immunotherapy, stratifying the risk of progression based on baseline cell size and density measurements from dMRI. This result, heretofore unreported and not achievable with standard dMRI indices (e.g., apparent diffusion coefficient), suggests that our approach may become a useful tool for precision imaging in oncology.

## 37 Introduction

38 Routine clinical Magnetic Resonance Imaging (MRI) focusses on visualising macroscopic  
39 anatomical features, as presence of tumours. Nonetheless, MRI also offers the possibility of  
40 measuring biological properties within each pixel of a three-dimensional (3D) scan – known as  
41 *voxel*. This approach, referred to as quantitative MRI (qMRI)<sup>1</sup>, involves the acquisition of multiple  
42 images, each featuring a different contrast, which are then analysed jointly with a mathematical  
43 model. qMRI provides promising metrics, which could become quantitative biomarkers  
44 complementing the qualitative assessment by the expert radiologist<sup>2</sup>. Diffusion MRI (dMRI) is a  
45 qMRI approach that sensitises the signal to water diffusion with magnetic field gradients<sup>1,3,4</sup>. Since  
46 diffusion in biological tissues is influenced by the microenvironment where diffusion takes place,  
47 dMRI ultimately enables the indirect estimation of properties at the micrometric scale<sup>5</sup>, such as  
48 the size of cells restricting water<sup>6,7</sup>. dMRI bridges the gap between macroscopic and microscopic  
49 imaging, and has found applications in brain<sup>5</sup>, spinal cord<sup>8</sup>, prostate<sup>6</sup>, breast<sup>9</sup> imaging and beyond.

50 Innovative dMRI techniques are also urgently needed in abdominal imaging, as in liver MRI<sup>10,11</sup>.  
51 The liver is a frequent site for cancer metastatisation<sup>12</sup>, and liver tumours are common targets for  
52 treatment response assessment in oncology. However, current response criteria such as RECIST<sup>13</sup>  
53 have limitations, in that they rely on MRI or computed tomography (CT) merely to measure tumour  
54 size, without accounting for changes under therapy at the cellular level. Novel dMRI metrics could  
55 enable the non-invasive characterisation of cancer microenvironments, shedding light on the  
56 composition of tumours that cannot be biopsied. The new readouts could also provide information  
57 on tumour heterogeneity, relevant in the development of treatment resistance<sup>14,15</sup>, and could better  
58 stratify patients eligible for treatments such as immunotherapy<sup>16</sup>, given the challenge of predicting  
59 which patients can benefit from these innovative drugs<sup>17</sup>. This would be a major advancement in  
60 oncology, as it may allow for personalised treatment planning, reductions in sample sizes in  
61 clinical trials, and ultimately improve patient outcomes<sup>18</sup>.

62 The most recent biophysical dMRI techniques describe the non-vascular liver tissue signal as the  
63 sum of contributions from intra-cellular and extra-cellular water<sup>19–21</sup>. While these models provide  
64 promising readouts<sup>22</sup>, their practical use in real-world settings is made unfeasible by i) the high  
65 number of dMRI images (and hence long scan time) required to support model fitting, and by ii)  
66 the requirement for specialised dMRI acquisitions<sup>23</sup>, beyond default examinations available in the  
67 scanner console. In this study we aim to tackle this unmet need by delivering a practical liver dMRI  
68 signal model that is truly feasible in hospital settings, i.e., on 1.5T or 3T systems, with scan time  
69 that does not exceed 15 minutes, and using vendor-provided dMRI sequences. With this objective  
70 in mind, we embraced the latest “histology-informed” dMRI development paradigm, which is  
71 based on informing signal model design with co-localised histology. The framework has shown  
72 promise in delivering dMRI approaches with unprecedented fidelity to cytoarchitecture<sup>24,25</sup>,  
73 maximising biological specificity<sup>26</sup>.

74 In this article, we aimed to identify a practical mathematical model that maximises the agreement  
75 of dMRI estimates of metrics such as cell size, to their underlying histological counterparts. We  
76 analysed a rich data set of dMRI scans and hematoxylin and eosin (HE)-stained images from  
77 excised mouse livers and patients' liver biopsies. We used these data to select the model  
78 maximising radiological-histological correlations, corroborating results with computer  
79 simulations. Afterwards, we demonstrated the clinical utility of the designed approach in one  
80 exemplificatory task, assessing response to immunotherapy in patients suffering from advanced  
81 solid tumours – an urgent, unmet need, given the lack of robust predictors of treatment response  
82 for this class of drugs<sup>17</sup>. In summary, our study delivers a liver dMRI approach that offers metrics  
83 with high fidelity to histopathology, and which is feasible in the clinic. The proposed method,  
84 based on a single-compartment model of restricted, intra-cellular diffusion, fitted to highly  
85 diffusion-weighted (DW) images, identified which patients progress faster from baseline dMRI  
86 scans. These results, while exploratory and requiring further confirmation, suggest that our dMRI  
87 framework could provide complementary information to standard-of-care imaging, and thus play  
88 a key role in oncology research and practice.

89

## 90 Results

### 91 Overview: data set

92 Fig. 1 illustrates the data used in this study. We will refer to data obtained in fixed mouse livers as  
93 *preclinical*, while to data obtained in cancer patients as *clinical*.

94

95 Preclinical data consists of pulsed gradient spin echo (PGSE) DW MRI scans of seven fixed mouse  
96 livers, performed *ex vivo* on a 9.4T Bruker system. It also includes whole-organ HE-stained  
97 sections, obtained at known radiographic position. We studied the livers of mice sacrificed as part  
98 of xenograft model development in prostate cancer. Six had been implanted with biopsies of  
99 prostate cancer patients, while one had not had any implantation. While the livers from the  
100 implanted mice did not grow any tumours, they feature a variety of pathologies, with three unique  
101 histopathological phenotypes (Fig. S1). The liver from the mouse with no implantation features  
102 normal liver structures, and we will refer to it as *Control*. Of the six implanted cases, two also  
103 show normal liver tissue, with normal representation of all hepatic structures. We will refer to  
104 these cases as *PatNA1* and *PatNA2* (patient biopsy implantation, but normal appearing). Another case  
105 exhibits generalised necrosis and diffuse acute and chronic inflammation surrounding necrotic  
106 areas, with presence of occluded thrombotic vessels. This specimen will be identified as *Patnec*  
107 (patient biopsy implantation, with necrosis). Finally, three specimens feature an immature,  
108 lymphoproliferative process, with various degrees of infiltration of small, lymphoid, atypical cells  
109 with abundant mitosis, which infiltrate portal vessels and sinusoidal capillaries, but without

110 producing tumours. These will be referred to as  $Pat_{inf1}$  to  $Pat_{inf3}$  (patient biopsy implantation, with  
111 lymphoid cell infiltration).

112

113 We obtained clinical data on cancer patients suffering from advanced solid tumours, participating  
114 in an ongoing imaging study at the Barcelona Vall d'Hebron Institute of Oncology (VHIO, Spain).  
115 The study involves the acquisition of MRI data, alongside clinical and biological information, in  
116 patients eligible for a phase I immunotherapy trial. We included data from 33 patients with liver  
117 malignancies (mean/std of age: 62.91/12.34 year; 16 male, 17 female). dMRI was based on  
118 diffusion-weighted (DW) echo planar imaging (EPI) scans performed on a 1.5T Siemens Avanto  
119 system (Twice-Refocussed Spin Echo (TRSE) DW-EPI) and on a 3T GE SIGNA Pioneer system  
120 (PGSE DW-EPI). We also obtained digitised HE-stained biopsies from one of the liver tumours.  
121 Biopsies were available for 18 patients, and were collected after dMRI, but before  
122 immunotherapy. Clinical outcome (progression-free survival (PFS)) was available for 30 patients,  
123 who effectively entered the immunotherapy trial.

124

125 We used dMRI-histology data to design the dMRI signal model ( $N = 25$ ) and dMRI-PFS data for  
126 immunotherapy response assessment ( $N = 30$ ).

127

## 128 **Overview: dMRI signal models**

129 We studied five dMRI biophysical models, accounting for restricted diffusion inside spherical cells  
130 and hindered diffusion in the extra-cellular space<sup>6,19,22</sup>. Models can be grouped into two families  
131 (Fig. 2.A; see Material and Methods).

132 The first family is more general, in that it does not make any assumption on which is higher  
133 between intra-/extra-cellular ADC ( $ADC_I$  and  $ADC_E$  from now on). It includes:

- 134 i. *Diff-in-exTD*: it accounts for restricted IC diffusion within spherical cells<sup>6</sup>, and hindered  
135 diffusion in the extra-cellular space, with diffusion time dependence (TD)<sup>27</sup> in both intra-  
136 /extra-cellular spaces<sup>28</sup>. The diffusion time quantifies the time during which water  
137 molecules can sense cellular barriers, before the MR image is acquired.
- 138 ii. *Diff-in-ex*: as previous model *Diff-in-exTD*, but neglecting TD in the extra-cellular space.  
139 Popular techniques such as IMPULSED<sup>19</sup> or VERDICT<sup>20</sup> are essentially implementations  
140 of this model.

141 Conversely, the second family explicitly assumes that  $ADC_E > ADC_I$ , similarly to related dMRI  
142 techniques (e.g., Restriction Spectrum Imaging<sup>29</sup>; power-law axon radius mapping<sup>7</sup>). It includes:

- 143 i. *Diff-in-exTDFast*: equivalent to *Diff-in-exTD*, ensuring that  $ADC_E > ADC_I$ .
- 144 ii. *Diff-in-exFast*: equivalent to *Diff-in-ex*, ensuring that  $ADC_E > ADC_I$ .

145           iii. *Diff-in*: a model where it is hypothesised that due to fast, extra-cellular diffusion, the extra-  
146           cellular signal is negligible, and the measured signal is dominated by intra-cellular water.

147

### 148           **Overview: dMRI metrics**

149           All models enable the estimation of *volume-weighted mean cell size* ( $vCS_{MRI}$ , expressed in  $\mu\text{m}$ )  
150           and *intra-cellular signal fraction* ( $F_{MRI}$ , dimensionless), which can be combined into an apparent  
151           *cell density per unit volume* ( $CD_{MRI} = F_{MRI}/vCS_{MRI}^3$ , expressed in  $\text{cell mm}^{-3}$ )<sup>20</sup>. For reference, we  
152           benchmarked these metrics against routine ADC (in  $\mu\text{m}^2 \text{ms}^{-1}$ ) and apparent diffusion excess  
153           kurtosis  $K$  (dimensionless) from diffusion kurtosis imaging (DKI)<sup>30</sup>, popular dMRI indices  
154           sensitive to cancer cellularity, easy to compute from short acquisitions<sup>20,31</sup>.

155

156           We processed HE-stained histological data with automatic cell detection<sup>32</sup> to derive histological  
157           counterparts of  $vCS_{MRI}$  and  $F_{MRI}$  at known radiographic location. The histological metrics were:  
158           histological volume-weighted mean cell size ( $vCS_{histo}$ , in  $\mu\text{m}$ ), intra-cellular area fraction ( $F_{histo}$ ,  
159           dimensionless), and cell density per unit area ( $CD_{histo}$ , in  $\text{cell mm}^{-2}$ ). We compared  $vCS_{histo}$  and  
160            $F_{histo}$  to  $vCS_{MRI}$  and  $F_{MRI}$  (Fig. 2B).

161

### 162           **A one-pool model of intra-cellular diffusion provides the most histologically meaningful** 163           **metrics**

164           Fig. 3A summarises the different dMRI models, while Fig. 3B reports values of the MRI-Histology  
165           *Total Correlation Score* (TCS) for all models. TCS measures the overall correlation between  
166           histological and radiological readouts of cell size and intra-cellular fraction, and is obtained by  
167           summing Pearson's correlation coefficients between  $vCS_{MRI}$  and  $vCS_{histo}$ , and between  $F_{MRI}$  and  
168            $F_{histo}$  (see Materials and Methods). Higher TCS point towards stronger histological-radiological  
169           correlation. Negative correlations reduce TCS, so they are penalised.

170

171           The bar plot in Fig. 3B highlights that dMRI models where  $ADC_E > ADC_I$ , shown in violet shades,  
172           provide consistently higher TCS values than models that do not make such an assumption (orange  
173           shades). We observe the highest TCS for model *Diff-in*. Note that Fig. 3 refers to TCS values  
174           obtained by fitting dMRI models only to high b-value images, as this provided the highest TCS  
175           figures. Fig. S2 reports TCS for model fitting performed to the whole set of diffusion images. In  
176           this case, TCS is lower, but again, models where  $ADC_E > ADC_I$  provide the highest TCS. In Fig.  
177           S2, *Diff-in-exFast* provides the highest TCS, although this is lower than *Diff-in* TCS in Fig. 3.

178

179           Fig. S3 reports rankings according to additional criteria, namely: the *Histology Fidelity Criterion*  
180           (HFC), measuring the sum of absolute errors in  $F$  and  $vCS$  estimation via dMRI, and the *Bayesian*

181 *Information Criterion* (BIC)<sup>33</sup>. BIC is commonly used in dMRI model development<sup>34,35</sup>; it  
182 quantifies the overall model fitting quality (penalizing model complexity), but without accounting  
183 for histological information. Lower HFC and lower BIC imply better model performance. Fig. S3  
184 reports the number of times, in percentage terms, that a model provides the lowest HFC and BIC  
185 across our  $N = 25$  MRI-histology cases. Results essentially confirm rankings seen on TCS: models  
186 hypothesising  $ADC_E > ADC_I$  are selected more frequently than models that do not do, according  
187 to HFC. The model *Diff-in* is the most selected model according to both BIC and HFC (fig. S3.B;  
188 fitting to high b-value images). Fig. S4 splits HFC and BIC rankings depending on the MRI  
189 scanner. In all cases, models with  $ADC_E > ADC_I$  (*Diff-in*, *Diff-in-exFast*, *Diff-in-exFastTD*) are  
190 selected more frequently than models *Diff-in-ex* and *Diff-in-ex-TD*. When fitting is performed only  
191 on high b-value images, *Diff-in* is the most selected model according to both BIC and HFC.

192

### 193 **Computer simulations confirm model selection from MRI measurements**

194 We performed Monte Carlo computer simulations to corroborate the model selection performed  
195 on *ex vivo* and *in vivo* dMRI data. The simulations consisted in generating synthetic dMRI signals  
196 according to the three dMRI protocols used in this study. We synthesised signals for a substrate  
197 made of packed spherical cells (Fig. S5), a common body dMRI tissue model<sup>6,19,22,23</sup>, and then  
198 performed model selection on the synthetic signals (see Materials and Methods). Supplementary  
199 Tables S1, S2, and S3 report TCS, HFC and BIC rankings from simulated signals. Results confirm  
200 that model *Diff-in* enables the best estimation of cell size and intra-cellular fraction in the vast  
201 majorities of cases, thus confirming *ex vivo* and *in vivo* MRI results.

202

### 203 **Our proposed approach: a one-compartment model of intra-cellular diffusion, fitted to high** 204 **b-values**

205 In view of all rankings reported above, our recommended modelling approach is the *fitting a one-*  
206 *compartment model of restricted, intra-cellular diffusion within spherical cells to high b-values*  
207 *images* ( $\approx 1800$  s/mm<sup>2</sup> *ex vivo*,  $\approx 900$  s/mm<sup>2</sup> *in vivo*) – referred to as model *Diff-in*.

208

### 209 **Cell size and density estimates from the proposed dMRI model correlate with histology**

210 We now report on the Pearson's correlation coefficient  $r$  between histology, *Diff-in* and DKI  
211 metrics. We consider correlations to be weak, moderate, and strong when  $|r| < 0.4$ ,  $|r| \geq 0.4$  but  
212  $|r| < 0.6$ , and  $|r| \geq 0.6$ .

213

214 Table 1 shows that the correlation between *Diff-in*  $F_{MRI}$  (intra-cellular fraction),  $vCS_{MRI}$  (cell size  
215 index) and  $CD_{MRI}$  (cell density) with their counterparts  $F_{histo}$ ,  $vCS_{histo}$  and  $CD_{histo}$  are  
216 respectively weak ( $r = 0.19$  between  $F_{MRI}$  and  $F_{histo}$ ), moderate ( $r = 0.44$  between  $vCS_{MRI}$  and

217  $vCS_{histo}$ ) and strong ( $r = 0.70$  between  $CD_{MRI}$  and  $CD_{histo}$ ). The weak correlation between  $F_{MRI}$   
218 and  $F_{histo}$  can be explained, at least in part, with the fact that  $F_{MRI}$  is a signal fraction, rather than  
219 an actual volume/area fraction (unlike  $F_{histo}$ ), i.e., it is influenced by T2/T1 differences between  
220 intra-cellular and residual extra-cellular signals<sup>36</sup>. Moreover,  $F_{MRI}$  estimation can be biased by  
221 unaccounted exchange between intra-/extra-cellular water<sup>21,37</sup>, which is not accounted for in our  
222 signal models. Conversely, the much higher correlations between  $vCS_{MRI}$  and  $vCS_{histo}$  and  
223 between  $CD_{MRI}$  and  $CD_{histo}$ , point towards the biological specificity of  $vCS_{MRI}$  and  $CD_{MRI}$ .

224

225 Table 1 also reports correlation coefficients for dMRI ADC and kurtosis  $K$ . Both ADC and  $K$   
226 exhibit significant, moderate correlations with histological properties, i.e., negative/positive  
227 correlation of ADC/ $K$  with cell density  $CD_{histo}$  ( $r = -0.47$  and  $0.43$  respectively) – a result entirely  
228 consistent with previous studies<sup>38,39</sup>. Significant correlations are also seen with  $F_{histo}$  ( $r = 0.40$ ,  $p$   
229  $= 0.048$  between  $K$  and  $F_{histo}$ ). These findings are in line with known literature: ADC and  $K$  are  
230 sensitive to the underlying tissue microstructure, but they are also unspecific, being surrogate  
231 metrics that conflate different histopathological characteristics into a single number.

232

233 Fig. S6 and Fig. S7 show Pearson's correlation coefficients for all possible pairs of metrics, in the  
234 form of correlation matrices. Correlations among dMRI metrics are seen, as a strong negative  
235 correlation between  $CD_{MRI}$  and  $vCS_{MRI}$  ( $r = -0.84$  for model *Diff-in-exFast* fitted at high b-value).  
236 This finding, which indicates that tighter cell packings per unit volume are achieved with smaller  
237 cells, appears biophysically plausible, being mirrored by histological  $CD_{histo}$  and  $vCS_{histo}$  ( $r = -$   
238  $0.88$  between  $CD_{histo}$  and  $vCS_{histo}$ ). Other weak-to-moderate correlations are seen, e.g.: between  
239  $K$  and  $vCS_{MRI}$  ( $r = -0.47$ ) and  $K$  and  $CD_{MRI}$  ( $r = 0.38$ ), which agree with the correlations observed  
240 between  $K$  and histological  $vCS_{histo}$  ( $r = -0.31$ ) and  $CD_{histo}$  ( $r = 0.43$ ). In general, metrics from  
241 dMRI models where  $ADC_E > ADC_I$  show stronger correlations with their histological counterparts  
242 than models *Diff-in-exTD* and *Diff-in-ex*. We observe the strongest dMRI-histology correlations  
243 for model *Diff-in* fitted to high b-value images.

244

### 245 **Metrics from the proposed dMRI model reveal intra-/inter-tumour characteristics**

246 Fig. 4 shows maps from the proposed dMRI model *Diff-in* alongside histological metrics in 3  
247 mouse livers, representative of the 3 phenotypes seen in our mouse data (*Control*, for normal liver  
248 structures; *Patinfl*, for small cell infiltration; *Patnec*, for necrosis). Visually, we observe excellent  
249 co-localisation between MRI slices and histology sections. The histological details reveal higher  
250 cellularity in sample *Patinfl* compared to *Control*, due to packing of small cells in between larger  
251 hepatocytes, or an alternation of areas with lower/ higher cell density in sample *Patnec*. These  
252 qualitative trends are confirmed in the histological maps  $F_{histo}$ ,  $vCS_{histo}$ ,  $CD_{histo}$ , with values in  
253 physiologically plausible ranges, as for example intra-cellular fractions around 0.75 and cell sizes

254 of the order of  $20 \mu\text{m}^{40,41}$ . Maps  $F_{MRI}$ ,  $vCS_{MRI}$  and  $CD_{MRI}$  replicate the contrasts seeing in their  
255 histological counterparts  $F_{histo}$ ,  $vCS_{histo}$  and  $CD_{histo}$ . Fig. S8 shows standard dMRI metrics,  
256 namely ADC and kurtosis excess  $K$ , in the same mouse livers. Visual trends highlight that the  
257 higher cell density of sample *Patinfl* translated to remarkably reduced ADC and increased  $K$   
258 compared to the *Control*. Lastly, Fig. S9 shows  $F_{MRI}$ ,  $vCS_{MRI}$  and  $CD_{MRI}$  maps from another model  
259 (*Diff-in-exFast*). Fig. S10 instead shows maps of the other metrics provided by models *Diff-in-*  
260 *exFast* and *Diff-in* (intrinsic cytosol diffusivity  $D_{0,I}$  and asymptotic  $ADC_E$ ,  $D_{E,\infty}$ ). The figures  
261 highlight that overall, spatial trends seen in maps from the selected model *Diff-in* agree with those  
262 seen in *Diff-in-exFast*, but metrics from the latter appear noisier. Metrics  $D_{0,I}$  and  $D_{E,\infty}$  show  
263 limited between-sample contrast, and are difficult to validate histologically.

264

265 Table S4 reports qualitative per-sample mean and standard deviation of all MRI and histology  
266 metrics in mice.  $F_{MRI}$  slightly underestimates  $F_{histo}$ , while  $vCS_{MRI}$  slightly overestimates  
267  $vCS_{histo}$ . We speculate that the discrepancies may be due, at least in part, to unaccounted factors  
268 such as variability in intrinsic cell shape/cytosol diffusivity<sup>42</sup> or water exchange<sup>21</sup>, and by the  
269 difficulty of relating accurately 2D histology to 3D MRI<sup>43</sup>.

270

271 Fig. 5 shows  $F_{MRI}$ ,  $vCS_{MRI}$  and  $CD_{MRI}$  maps in patients, alongside biopsies. Histopathological  
272 assessment highlights the variety of characteristics that can coexist within advanced solid tumours,  
273 e.g.: areas of fibrosis; localised areas of tightly packed cancer cells, surrounded by stromal fibres;  
274 necrosis. dMRI  $F_{MRI}$ ,  $vCS_{MRI}$ ,  $CD_{MRI}$  show contrasts that are plausible with such histopathological  
275 features. For example, in a breast cancer liver metastasis in Fig. 5, we observe a core of low intra-  
276 cellular fraction  $F_{MRI}$  and low cell density  $CD_{MRI}$ , compatible with necrosis. In a HCC case instead,  
277 we see areas of high  $F_{MRI}$  and high  $CD_{MRI}$ , surrounded by lower  $F_{MRI}$  and lower  $CD_{MRI}$ ,  
278 potentially indicating the alternation of high cell densities with fibrotic tissue. Fig. S11 shows  
279 routine dMRI ADC and  $K$  in the same tumours. Spatial trends are also compatible with the  
280 histology, e.g., high ADC and low  $K$  are seen in the necrotic core of the breast cancer tumour.  
281 Supplementary Fig. S12 shows  $F_{MRI}$ ,  $vCS_{MRI}$  and  $CD_{MRI}$  from model *Diff-in-exFast*. Image  
282 contrasts match visually those seen in the same metrics from model *Diff-in* (the proposed  
283 approach), giving confidence of the overall robustness of the biophysical modelling framework.  
284 Nevertheless, maps appear noisier. Fig. S13 shows intra-cellular cytosol diffusivity  $D_{0,I}$   
285 asymptotic  $ADC_E$  ( $D_{E,\infty}$ ) in the same tumours. Their speckled appearance suggests that these  
286 metrics are difficult to measure accurately *in vivo*<sup>19,44</sup>.

287

288 **Metrics from the proposed dMRI model stratify the risk of cancer progression in**  
289 **immunotherapy**



290 Finally, we demonstrate the potential utility of the proposed liver dMRI model in an  
291 exemplificatory response assessment task. Fig. 6 reports on the PFS stratification based on *Diff-in*  
292 metrics. Panels on the left report results from Kaplan-Meier analyses, log-rank tests and Cox  
293 regressions performed after binarising dMRI metrics (higher/lower than the median of the cohort).  
294 Panels on the right report results from Cox regressions assessing the continuous dependence of  
295 PFS on *Diff-in* metrics. We detect a statistically significant dependence of the risk of progression  
296 on baseline  $vCS_{MRI}$  (log-rank test:  $p = 0.047$ , Fig. 6C) and  $CD_{MRI}$  (log-rank test:  $p = 0.035$ , Fig.  
297 6E). These differences correspond to statistically significant Hazard Ratios (HRs) from Cox  
298 regression (HR = 0.47,  $p = 0.050$  for binarised  $vCS_{MRI}$ ; HR = 2.36,  $p = 0.043$  for binarised  $CD_{MRI}$ ).  
299 The risk of progression is about twice as high in patients whose baseline cell size  $vCS_{MRI}$  is smaller  
300 than the median  $vCS_{MRI}$ , or whose cell density  $CD_{MRI}$  is higher than the median  $CD_{MRI}$ .  
301 Importantly, we obtained similar results when  $vCS_{MRI}$  and  $CD_{MRI}$  were not binarised, but rather  
302 used as continuous predictors in Cox regressions (right panels in Fig. 6). In this latter case, the HR  
303 was statistically significant for  $vCS_{MRI}$  (HR = 0.65,  $p = 0.034$ , Fig. 6D), and it approached  
304 statistical significance for  $CD_{MRI}$  (HR = 1.40,  $p = 0.055$ , Fig. 6F). These association are not  
305 confounded by age, sex or baseline tumour volume (Supplementary Table S5; HR = 0.59,  $p = 0.02$   
306 for  $vCS_{MRI}$ ; HR = 1.65,  $p = 0.01$  for  $CD_{MRI}$ ).

307  
308 Fig. 7 and supplementary Fig. S14, Fig. S15 and Fig. S16 report on response assessment based on  
309 on all other dMRI metrics (routine  $ADC$  and  $K$  in Fig. 7; cytosol diffusivity  $D_{0,I}$  for model *Diff-in*  
310 in Fig. S14; vascular fraction  $f_V$  in Fig. S15; all metrics from model *Diff-in-exFast* in Fig. S16).  
311 While the estimated HRs for metrics  $vCS_{MRI}$ ,  $F_{MRI}$  and  $CD_{MRI}$  from dMRI model *Diff-in-exFast*  
312 are in the same direction as those from model *Diff-in*, their association with the probability of  
313 progression is weaker (HR = 1.53,  $p = 0.05$  for  $CD_{MRI}$ ; Table S5). We do not detect any association  
314 between baseline  $ADC$  and  $K$  and the probability of progression (Fig. 7 and Table S5).

315

## 316 Discussion

317 The latest liver dMRI models aim to disentangle intra-cellular and extra-cellular water  
318 contributions to the total signal<sup>16,19,22,23</sup>. This powerful approach enables the estimation of  
319 innovative tissue property maps, but its clinical deployment is hampered by the high number of  
320 unknown tissue parameters to estimate, which requires impractically long dMRI  
321 acquisitions<sup>19,45,46</sup>. With this challenge in mind, this paper delivers a practical implementation of a  
322 two-compartment dMRI signal model, tailored for liver imaging, and truly feasible in the clinic.  
323 Through histology-informed model selection, we design a compact dMRI framework consisting  
324 of fitting a one-pool model of restricted intra-cellular diffusion to highly DW images. The  
325 framework provides cell size and density estimates that correlate with histology, and which enable  
326 the stratification of the risk of cancer progression under immunotherapy.

327

328 To find the optimal dMRI signal implementation, we analysed co-localised dMRI and histology  
329 data (N = 25) from fixed mouse livers and from cancer patients. We compared 5 signal models,  
330 each fitted according to two distinct strategies, and ranked them for their ability to estimate intra-  
331 cellular fraction and cell size, as seen on histology. Rankings unequivocally suggest the highest  
332 radiological-histological agreement is obtained by *fitting a single-compartment model of restricted*  
333 *diffusion within spherical cells* – a model here referred to as *Diff-in* –, to images acquired with b-  
334 values higher than approximately 900 s/mm<sup>2</sup> *in vivo* and 1800 s/mm<sup>2</sup> *ex vivo*. Interestingly, our  
335 central result, confirmed by Monte Carlo computer simulations, points towards the fact that  
336 simpler models of diffusion can provide the highest fidelity to the underlying histology, if deployed  
337 in appropriate measurement regimes. In practice, our approach suggests that focussing on  
338 measurement regimes where the signal is dominated by intra-cellular diffusion, may enable the  
339 deployment of simpler models, which still suffice to capture salient microstructural features<sup>7,47-49</sup>.  
340 Notably, our model selection results are consistent with the fact recent estimates of the extra-  
341 cellular liver ADC, as high as 2.5 μm<sup>2</sup>/ms<sup>19</sup>. Such a high  $ADC_E$  implies that the extra-cellular  
342 signal would decay to roughly 5% or less of its non-DW value even for b-values of 1200 s/mm<sup>2</sup>  
343 ( $\exp(-b ADC_E) \approx 0.05$  for  $b = 1200 \text{ s/mm}^2 = 1.2 \text{ ms}^{-1} \mu\text{m}^2$  and  $ADC_E = 2.5 \mu\text{m}^2 \text{ ms}^{-1}$ ), justifying  
344 the use of single-compartment model of intra-cellular diffusion<sup>7,44,50</sup>.

345  
346 Importantly, we conducted dMRI model selection using a variety of criteria, namely: TCS (overall  
347 correlation between dMRI and histology), HFC (accuracy in histological property estimation via  
348 dMRI), and BIC<sup>35</sup> (dMRI model quality of fit, penalising model complexity). In general, all criteria  
349 point towards the same direction, with model *Diff-in* fitted to high b-value images being the top-  
350 ranking model. We would also like to emphasise that while we used 15 *in vivo* dMRI scans for  
351 both model design and for the clinical demonstration, the same liver dMRI model implementation  
352 (i.e., fitting model *Diff-in* on high b-value images) would have been selected had we only looked  
353 at the *ex vivo* mouse data or at *in silico* signals (Fig. S4, Tables S1 to S3). This fact gives confidence  
354 on the robustness and generalisability of our model design. Another important observation is that  
355 both TCS and HFC, which are histology-informed, suggest that models constraining the extra-  
356 cellular ADC to be higher than the intra-cellular ADC, outperform models without such a  
357 constraint. Such a better performance does not stand out as clearly when looking at BIC rankings  
358 instead (e.g., Fig. S3.A, Fig. S4.A, Fig. S4.B, Fig. S4.C). This minor discrepancy can be  
359 understood considering that a good fitting quality may not necessary imply accurate parameter  
360 estimation in presence of noise<sup>26,44</sup>. It also stresses the importance of informing dMRI modelling  
361 with histology, for improved biological specificity.

362  
363 After selecting a practical dMRI model implementation, we investigated its utility in an  
364 exemplificatory response assessment task. Immunotherapy has shown promise in several  
365 cancers<sup>16</sup>. However, only a small fraction of patients truly benefits from this class of drugs, and  
366 their identification prior to treatment is extremely challenging<sup>17</sup>. With this in mind, we investigated

367 whether it is possible to stratify the probability of progression under immunotherapy given baseline  
368 dMRI metrics within liver tumours ( $N = 30$ ). Several, independent statistical tests consistently  
369 point towards the fact that smaller baseline dMRI cell sizes and higher dMRI cell densities are  
370 associated to faster cancer progression (shorter PFS). To our knowledge, this is the first time that  
371 such advanced dMRI markers have been tested for patient stratification in immunotherapy *in vivo*.  
372 The deleterious impact of higher cell density on PFS is in line with other studies focussing on  
373 different treatments, where higher tumour cellularity has been associated with higher cancer  
374 aggressiveness or worse prognosis. In CRC liver metastasis resection, for example, high cell  
375 density in resected metastases has been associated to shorter disease-free survival<sup>51</sup>. Conversely,  
376 in breast cancer, lower tumour cellularity has been associated to pathologic complete response in  
377 chemo-free dual HER2 blockade treatment (for HER2-positive breast cancer)<sup>52</sup>, as well as longer  
378 survivals in neoadjuvant chemotherapy<sup>53</sup>. The significant association between PFS and dMRI cell  
379 size/density reported here is promising, and motivates future studies to confirm it.

380

381 We benchmarked the proposed dMRI approach against well-established DKI apparent diffusion  
382 and kurtosis coefficients ( $ADC$  and  $K$ )<sup>30</sup>.  $ADC$  and  $K$  are easy to compute with compact dMRI  
383 acquisitions, and are sensitive to cancer cellularity<sup>46</sup>, a fact confirmed by our data. However, in  
384 our cohort, neither of  $ADC$  and  $K$  showed statistically significant associations with clinical PFS.  
385 This may due, at least partly, to the fact that  $ADC$  and  $K$  are semi-quantitative, protocol-dependent  
386 metrics, whose value can change as function of factors as the diffusion time<sup>46,54</sup>. Here, we did not  
387 perform inter-scanner harmonisation deliberately, to stress the quantitative nature of our cell  
388 size/density mapping approach, which inherently accounts for inter-scanner protocol differences.  
389 However, it is possible that better performances for semi-quantitative  $ADC$  and  $K$  may be obtained  
390 by adopting inter-scanner harmonisation<sup>55</sup>.

391

392 We would like to acknowledge the following potential limitations. Firstly, our sample size ( $N =$   
393  $25$  for model development;  $N = 30$  for the clinical demonstration) is relatively small. This paper  
394 provides a first demonstration of the potential utility of the proposed *Diff-in* approach. The  
395 demonstration is unique of its kind, since it reports heretofore undescribed dMRI-based  
396 stratification in immunotherapy. Nonetheless, while works proposing related dMRI techniques  
397 relied on similar<sup>23,36</sup>, if not even smaller<sup>19,20</sup>, sample sizes, we acknowledge that our exploratory  
398 findings require further confirmation in larger cohorts.

399

400 Secondly, we point out that results from any dMRI-histology comparison should always be taken  
401 with care. Here we related dMRI metrics obtained *in vivo* to histological indices from biopsies.  
402 While we were able to identify the tumours from which the biopsies were taken, we could not  
403 identify exactly the tumour area that was biopsied. This may imply that the biopsies are not fully  
404 representative of the tumour microenvironment in its entirety. Also, and most importantly,

405 histology has its own limitations, since it provides cell property estimates that may not be, *per se*,  
406 fully accurate. For example, routine HE histology is an inherently 2D technique, unlike 3D MRI.  
407 Moreover, it is affected by artifacts (e.g., due to dehydration, paraffin embedding, imperfect  
408 staining, cutting, etc<sup>56</sup>), and the automatic processing of large fields-of-view requires trading off  
409 between sensitivity and specificity. We took steps to mitigate these issues, e.g., by accounting for  
410 biases due to tissue shrinkage. Nonetheless, our histology-derived estimates of cell properties are  
411 likely biased versions of the true figures.

412

413 We would also like to acknowledge that the proposed dMRI approach neglects other potentially  
414 relevant microstructural properties, such as water exchange between intra-/extra-cellular  
415 spaces<sup>21,37</sup>, presence of cell size/cytosolic diffusivity distributions<sup>42,57</sup>, or intra-compartmental T2  
416 or T1<sup>36</sup>. On the one hand, ignoring these properties may have biased the estimation of  $F_{MRI}$  and  
417  $vCS_{MRI}$ <sup>21,37</sup>. On the other hand, properties such as exchange rates, overlooked in our model, may  
418 be relevant markers of cellular stress *per se*. In future, we plan to incorporate these properties in  
419 our models, while ensuring the clinical feasibility of the dMRI protocols required to fit them.

420

421 To conclude, *this study delivers a practical liver dMRI signal model consisting of a single-*  
422 *compartment of restricted diffusion within spherical cells, which should be fitted to b-values higher*  
423 *than, approximately, 900 s/mm<sup>2</sup> in vivo.* This model offers estimates of cell size and cell density  
424 that are correlated to the underlying histology, and which may provide complementary information  
425 to routine volumetric tumour burden assessment, for example by stratifying the risk of cancer  
426 progression in immunotherapy. Striving to bringing precision imaging one step closer to the clinic,  
427 we release our approach as an easy-to-use, open-source Python implementation, which will be  
428 freely accessible online.

429

## 430 **Methods**

### 431 **dMRI models**

432 Common biophysical body dMRI signal models<sup>6,19,20,50,58,59</sup> describe the signal as arising from  
433 three, non-exchanging proton pools: vascular water; restricted, intra-cellular water; hindered,  
434 extra-cellular, extra-vascular water. The dMRI signal for a PGSE measurement at b-value  $b$ ,  
435 gradient duration/separation  $\delta/\Delta$ , and echo time TE is

436

$$437 \quad s = s_0 \left( f_V e^{-\frac{TE}{T_{2V}}} a_V + (1 - f_V) \left( f_I e^{-\frac{TE}{T_{2I}}} a_I + (1 - f_I) e^{-\frac{TE}{T_{2E}}} a_E \right) \right). \quad (1)$$

438

439 Above,  $s_0$  is the apparent proton density,  $f_V$  is the voxel vascular signal fraction,  $f_I$  is the tissue  
 440 intra-cellular signal fraction,  $T2_V/T2_I/T2_E$  and  $a_V/a_I/a_E$  are compartment-wise T2 and diffusion-  
 441 weighting factors.

442  $a_V$  captures intra-voxel incoherent motion (IVIM) effects<sup>60</sup>. *In vivo*, the IVIM vascular ADC  
 443 ranges approximately<sup>61</sup> [15; 60]  $\mu\text{m}^2 \text{ms}^{-1}$ . For this reason, for  $b > 100 \text{ s/mm}^2$ , the vascular signal  
 444 vanishes ( $a_V \approx 0$ ), and Eq. (1) reduces to<sup>19</sup>

445

$$446 \quad s = s_0 (1 - f_V) \left( f_I e^{-\frac{TE}{T2_I}} a_I + (1 - f_I) e^{-\frac{TE}{T2_E}} a_E \right). \quad (2)$$

447

448 A common model for  $a_I$  in Eq. 2 is that of restricted diffusion within spheres of diameter  $L$ <sup>19,20</sup>:

449

$$450 \quad a_I = e^{-b \text{ADC}_I(\delta, \Delta, D_{0,I}, L)}, \quad (3)$$

451

452 where

453

$$454 \quad \text{ADC}_I = \frac{2}{D_{0,I} \delta^2 (\Delta - \delta/3)} \sum_{m=1}^{\infty} \frac{\alpha_m^{-4}}{\alpha_m^2 R^2 - 2} \left( 2\delta - \frac{2 + e^{-\alpha_m^2 D_{0,I} (\Delta - \delta)} - 2e^{-\alpha_m^2 D_{0,I} \delta} - 2e^{-\alpha_m^2 D_{0,I} \Delta} + e^{-\alpha_m^2 D_{0,I} (\Delta + \delta)}}{\alpha_m^2 D_{0,I}} \right) \quad (4)$$

455

456

457 is the Gaussian phase distribution approximation of the intra-cellular ADC<sup>62</sup>. Above,  $\alpha_m$  is the  $m$ -  
 458 th root of  $\alpha_m R J'_{3/2}(\alpha_m R) - 0.5 J_{3/2}(\alpha_m R) = 0$ ,  $J_{3/2}(x)$  is the Bessel function of the first kind and order  
 459  $3/2$ , and  $J'_{3/2}(x)$  its first-order derivative.  $\text{ADC}_I$  depends on the intrinsic cytosol diffusivity  $D_{0,I}$  and  
 460 on the cell size  $L = 2R$  ( $R$ : radius;  $L$ : diameter). Noting that dMRI-derived  $L$  represents a volume-  
 461 weighted mean cell size statistics<sup>7,42</sup>, we will refer to it as *volume-weighted cell size (vCS)*.

462

463 Conversely, the extra-cellular, extra-vascular signal may be described in terms of hindered  
 464 diffusion in a tortuous space<sup>19,27,59</sup>:

465

$$466 \quad a_E(b, \Delta) = e^{-b \text{ADC}_E(\Delta, D_E, \infty, \beta)}, \quad (5)$$

467

468 with

469

$$470 \quad ADC_E(\Delta, D_{E,\infty}, \beta) = D_{E,\infty} + \frac{\beta}{\Delta}. \quad (6)$$

471

472 In Eq. 6,  $D_{E,\infty}$  is the asymptotic<sup>59</sup>  $ADC_E$  for  $\Delta \rightarrow \infty$ .

473

### 474 The 5 implementations of the two-compartment model

475 We investigated 5 implementations of Eq. 2, divided into two families. The first family includes  
476 models that do not make assumptions on which of  $ADC_I/ADC_E$  is higher:

- 477 i. *Diff-in-exTD*: the most general model, relying on the full expression of  $ADC_E$  in Eq. 6;
- 478 ii. *Diff-in-ex*: a simpler implementation of *Diff-in-exTD* that neglects extra-cellular TD ( $\beta = 0$   
479 in Eq. 6).

480 In the second family of models, we constrain  $ADC_E > ADC_I$ . It includes

- 481 i. *Diff-in-exTDFast*: equivalent to *Diff-in-exTD*, with the lower bound for  $D_{E,\infty}$  ensuring  
482  $ADC_E > ADC_I$  for any  $L$ .
- 483 ii. *Diff-in-exFast*: equivalent to *Diff-in-ex*, but again ensuring that  $ADC_E > ADC_I$  for any  $L$ .
- 484 iii. *Diff-in*: a model where the extra-cellular signal is negligible compared to the intra-cellular  
485 one, due to  $ADC_E$  being much larger than  $ADC_I$ , so that Eq. 2 simplifies to

486

$$487 \quad s = s_0 (1 - f_V) f_I e^{-\frac{TE}{T2_I}} a_I(b, \delta, \Delta, D_{0,I}, L). \quad (7)$$

488

489 In all models we used  $T2_I \approx T2_E \doteq T2_T$ , given the challenge of resolving accurately multiple T2  
490 constants<sup>20,36</sup>.

491

### 492 Fitting

493 We fitted the 5 models using custom-written Python routines, based on objective function  
494 minimisation initialised by a grid search. The objective function was  $f_{obj} = -\ln(\lambda)$ , where  $\lambda$  is  
495 the offset-Gaussian likelihood<sup>34</sup>. Fitting provides estimates of  $vCS$  and voxel intra-cellular signal  
496 fraction

497

$$498 \quad F = (1 - f_V) f_I. \quad (8)$$

499

500 We also combined  $vCS$  and  $F$  into a cell density per unit volume<sup>20</sup>

501

$$502 \quad CD = \frac{F}{vCS^3}. \quad (9)$$

503

## 504 **Preclinical data**

### 505 Animals

506 We obtained data from 7 fixed livers of NOD.Cg-Prkdc<sup>scid</sup> IL2rg<sup>tm1Wjl</sup>/SzJ mice. All experimental  
507 protocols were approved and monitored by the Vall d'Hebron Institute of Research Animal  
508 Experimentation Ethics Committee (CEEA; registration number 68/20) in accordance with  
509 relevant local and EU regulations. We studied six livers from mice implanted with cells derived  
510 from biopsies of prostate cancer patients, as part of an ongoing study, plus an additional liver from  
511 a mouse without any implantation. We implanted one tumor biopsy core with growth factor-  
512 enriched Matrigel (Corning) subcutaneously in the flank of each mice. We derived tissue from the  
513 following biopsies: iliac bone metastasis biopsy (metastatic castration-resistant prostate cancer,  
514 presenting with bone metastasis and Gleason score 3+4 adenocarcinoma); prostate biopsy (patient  
515 with metastatic hormone-sensitive prostate cancer, presenting with bone metastasis and Gleason  
516 score 5+4 adenocarcinoma); two liver biopsies (patient with metastatic castration-resistant prostate  
517 cancer, presenting with bone and visceral metastasis and Gleason score 4+4 acinar  
518 adenocarcinoma; patient with metastatic hormone-sensitive prostate cancer, presenting with bone  
519 and liver metastasis and Gleason score 4+4 adenocarcinoma). After implantation, we measured  
520 tumour size using calipers and monitored mouse weight weekly, sacrificing animals by cervical  
521 dislocation under general anesthesia when tumour volume exceeded 2000 mm<sup>3</sup>. We collected the  
522 livers, fixed them overnight in formalin, and transferred them to phosphate-buffered saline (PBS)  
523 solution.

524

### 525 MRI

526 We scanned livers on a 9.4T Bruker Avance system at room temperature. Livers were tightened  
527 with sewing thread to a histology cassette and placed into a Falcon<sup>®</sup> tube, filled with PBS solution.  
528 A 1-channel birdcage coil was used (excitation/reception). The protocol included a T2-weighted  
529 fast spin echo sequence (resolution: 144  $\mu\text{m} \times 144 \mu\text{m} \times 2.216 \text{ mm}$ ) and PGSE dMRI (Fig. S17A;  
530 TR = 2700 ms; resolution: 386  $\mu\text{m} \times 386 \mu\text{m}$ ; matrix size: 86  $\times$  86; 4 slices, 2.216 mm-thick, NEX  
531 = 1). The protocol featured:  $\delta = 10 \text{ ms}$ ,  $\Delta = \{15, 30\} \text{ ms}$ , 10 linearly spaced b-values for each  $\Delta$   
532 (minimum/maximum nominal b: 0/2800 s/mm<sup>2</sup>). DW images corresponding to  $\Delta = 15 \text{ ms}$  were  
533 acquired at each of TE = {31, 45, 65} ms, and to  $\Delta = 30 \text{ ms}$  at each of TE = {45, 65} ms. We i)  
534 denoised dMRI scans with Marchenko-Pastur Principal Component Analysis (MP-PCA) Python  
535 denoising<sup>63</sup> (kernel: 7 $\times$ 7 $\times$ 3), ii) mitigated Gibbs ringing (MrTriX3 local sub-voxel shift method<sup>64</sup>),

536 and iii) corrected temporal signal drifts by assessing signal changes in a PBS solution region,  
537 accounting for TE (PBS T2: 500 ms).

538 Finally, we fitted the *Diff-in-exTD*, *Diff-in-exTDFast*, *Diff-in-ex*, *Diff-in-exFast* and *Diff-in* models  
539 voxel-by voxel (tissue parameter bounds: [0; 1] for  $f_I$ ; [0.8; 2.6]  $\mu\text{m}^2 \text{ms}^{-1}$  for  $D_{0,I}$ ; [8; 40]  $\mu\text{m}$  for  
540  $vCS$ ; [0.8; 2.6]  $\mu\text{m}^2 \text{ms}^{-1}$  for  $D_{E,\infty}$  in models *Diff-in-ex* and *Diff-in-exTD* and [1.75; 2.6]  $\mu\text{m}^2 \text{ms}^{-1}$   
541 in models *Diff-in-exFast* and *Diff-in-exTDFast*; [0; 10]  $\mu\text{m}^2$  for  $\beta$  in models *Diff-in-ex-TD* and  
542 *Diff-in-exTDFast*). For fitting, we fixed  $f_V$  and  $T2_T$  to values obtained through a two-pool  
543 vascular-tissue model<sup>65</sup> (fitting bounds: [0; 1] for  $f_V$ ; [5; 80] ms for  $T2_T$ ). Fitting was performed  
544 i) on all images with  $b > 1000 \text{ s/mm}^2$  (suppressing vascular signals, referred to as *fitting on whole*  
545 *image set*); ii) on  $b > 1000 \text{ s/mm}^2$  images (*high b-value fitting*). In our *ex vivo* data, the vascular  
546 signal captures PBS solution contamination (PBS ADC: roughly  $2.4 \mu\text{m}^2 \text{ms}^{-1}$ ). For this reason,  
547 we adopted a b-value threshold of  $1000 \text{ s/mm}^2$  to achieve acceptable PBS signal suppression. We  
548 used instead a minimum b-value of  $1800 \text{ s/mm}^2$  for high b-value fitting (minimising extra-cellular  
549 contributions), given the reduction in intrinsic tissue diffusivity expected *ex vivo*.

550

551 For comparison, we computed ADC and apparent diffusion excess kurtosis  $K$  by fitting

552

$$553 \quad s = s_0 e^{-b \text{ADC} + \frac{1}{6}K(b \text{ADC})^2} \quad (10)$$

554

555 to DW images acquired at  $TE = 45 \text{ ms}$ ,  $\Delta = 30 \text{ ms}$ , with in-house Python code.

556

### 557 Histology

558 After MRI, samples underwent histology. We cut two  $4 \mu\text{m}$ -thick histological sections at known  
559 position, stained them with HE, and digitised them (Hamamatsu C9600-12 slide scanner;  $0.227$   
560  $\mu\text{m}$  resolution). An experienced pathologist (S.S.) inspected images qualitatively. We then  
561 processed them with the automatic cell detection tool of QuPath<sup>32</sup>, obtaining per-cell area  $A$  and  
562 diameter  $l = \sqrt{\frac{4}{\pi}A}$ . Afterwards, we split images into  $386 \mu\text{m} \times 386 \mu\text{m}$  patches (matching the MRI  
563 resolution), computing patch-wise histological volume-weighted cell size  $vCS_{histo}$ , intra-cellular  
564 area fraction  $F_{histo}$  and cell density per unit area  $CD_{histo}$ <sup>42</sup>.  $vCS_{histo}$ , defined as

565

$$566 \quad vCS_{histo} = \left( \frac{\langle l^7 \rangle}{\langle l^3 \rangle} \right)^{\frac{1}{4}}, \quad (11)$$

567



568 is a more accurate counterpart of dMRI cell size than the arithmetic mean<sup>7,42</sup>  $aCS_{histo} = \langle l \rangle$ .  
569 We accounted for biases coming from: i) estimating the size of 3D objects from 2D views (bias  
570 1), ii) tissue shrinkage (bias 2), by rescaling  $vCS_{histo}$  and  $CD_{histo}$ . The final  $vCS_{histo}$  estimate was  
571 1.4616 times larger than the value obtained from direct image processing ( $1.4616 = 1.2732 \times 1.148$ ;  
572 1.2732, derived from the theory of spherical caps, accounts for bias 1; 1.148 accounts for bias 2,  
573 and corresponds to a plausible shrinkage of 12.9% following dehydration, clearing and paraffin  
574 embedding<sup>56</sup>). The final  $CD_{histo}$  estimate was 1.318 times smaller than the value derived from  
575 direct image processing, since 1 mm<sup>2</sup> of shrunk tissue corresponds to  $1.148 \times 1.148 \text{ mm}^2 = 1.318$   
576 mm<sup>2</sup> of unprocessed tissue (plausible shrinkage 12.9%<sup>56</sup>). Lastly, we co-registered histological  
577 maps to MRI<sup>42</sup> using DiPy<sup>66</sup>.

578

## 579 **Clinical data**

### 580 Cohort

581 We obtained data from patients suffering from advanced solid tumours, recruited for an ongoing  
582 imaging study approved by the Vall d'Hebron University Hospital Ethics committee  
583 (PR(AG)29/2020). Patients, eligible for a phase I immunotherapy trial at VHIO (Barcelona,  
584 Spain), provided informed written consent to participate in the imaging study. We included 33  
585 patients with liver malignancies (mean/std of age: 62.91/12.34 year; 16 male, 17 female), of which  
586 3 suffered from primary HCC, while 30 had liver metastases from different primary cancers (10  
587 colon, 8 melanoma, 3 rectal, 2 ovarian, 2 gastric, 2 breast, 1 renal, 1 endometrial, 1 ureteral). We  
588 obtained baseline dMRI scans (i.e., acquired immediately before starting immunotherapy), and  
589 digitised HE-stained biopsies from one of the imaged liver tumours. We obtained biopsies from  
590 18 patients (6 scanned at 1.5T, 12 at 3T), collected after baseline dMRI. 30 out of 33 patients  
591 finally entered the immunotherapy trial after screening; for them, a clinical outcome in the form  
592 of PFS was available. PFS represents the lag between therapy starting date and progression or  
593 death (whichever occurs first), with progression determined via RECIST<sup>13</sup>, or in case of  
594 established clinical worsening.

595

### 596 MRI

597 We imaged patients at the level of the abdomen. We scanned 11 patients on a 1.5T Siemens Avanto  
598 scanner using the vendor 18-channel body coil for detection. The protocol included a T2-weighted  
599 fast spin echo scan (resolution:  $1.4 \times 1.4 \times 5 \text{ mm}^3$ ; 32 slices; TR = 4500 ms; TE = 82 ms; echo  
600 train length: 29; NEX = 8; GRAPPA = 2) and fat-suppressed DW TRSE (Fig. S17B) EPI (dMRI  
601 scan time: 16 minutes). It featured: resolution:  $1.9 \times 1.9 \times 6 \text{ mm}^3$ ; 32 slices; TR = 7900 ms;  
602 bandwidth 1430 Hz/pixel; averaging of 3 orthogonal diffusion directions  $\times$  2 signal averages  
603 (effective NEX = 6); GRAPPA factor of 2; 6/8 partial Fourier imaging. The dMRI protocol  
604 consisted of  $b = \{0, 50, 100, 400, 900, 1200, 1600\} \text{ s/mm}^2$ , each for TE =  $\{93, 105, 120\} \text{ ms}$ . One  
605 additional image ( $b = 0 \text{ s/mm}^2$ ; TE = 93 ms) was acquired with reversed phase encoding polarity.

606 The gradient timings (Fig. S17B) were:  $\delta_1 = 8.9$  ms,  $\delta_2 = 17.6$  ms,  $\delta_3 = 20.4$  ms,  $\delta_4 = 6.0$  ms,  $\Delta_{1,2}$   
607 = 17.4 ms and  $\Delta_{1,4} = 63.9$  ms when TE = 93 ms;  $\delta_1 = 13.2$  ms,  $\delta_2 = 19.3$  ms,  $\delta_3 = 24.8$  ms,  $\delta_4 = 7.7$   
608 ms,  $\Delta_{1,2} = 21.7$  ms and  $\Delta_{1,4} = 74.2$  ms when TE = 105 ms;  $\delta_1 = 18.9$  ms,  $\delta_2 = 21.0$  ms,  $\delta_3 = 30.5$   
609 ms,  $\delta_4 = 9.5$  ms,  $\Delta_{1,2} = 27.5$  ms and  $\Delta_{1,4} = 87.5$  ms when TE = 120 ms. The b-value is

610

$$611 \quad b = \gamma^2 G^2 \left( \delta_1^2 (\Delta_{1,2} - \delta_1) + \frac{2}{3} (\delta_1 + \delta_2)^3 + (\delta_1 + \delta_2 - \delta_3)^2 (\Delta_{1,4} - \Delta_{1,2} - \delta_2 - \delta_3) \right). \quad (12)$$

612

613 We scanned 22 more patients on a 3T GE SIGNA Pioneer scanner, using the vendor 48-channel  
614 torso coil for signal reception, with 32 channels enabled for detection. The protocol included a  
615 respiratory-gated T2-weighted fast spin echo scan (resolution:  $1.4 \times 1.4 \times 6$  mm<sup>3</sup>; 32 slices; TR =  
616 4615 ms; TE = 52.86 ms; echo train length: 16) and respiratory-gated, fat-suppressed PGSE (Fig.  
617 S10A) EPI (dMRI scan time: 16 minutes). It featured: resolution:  $2.4 \times 2.4 \times 6$  mm<sup>3</sup>; 32 slices; TR  
618 = 6000 ms; bandwidth 1953 Hz/pixel; averaging of 3 orthogonal diffusion directions  $\times$  2 signal  
619 averages (effective NEX = 6); ASSET factor of 2. The dMRI protocol consisted of  $b = \{0, 50, 100,$   
620  $400, 900, 1200, 1500\}$  s/mm<sup>2</sup>, each for TE =  $\{75, 90, 105\}$  ms. The gradient timings (Fig. S17A)  
621 were: gradient duration  $\delta = \{0.0, 3.9, 5.2, 9.2, 15.0, 18.2, 21.0\}$  ms for TE = 75 ms,  $\delta = \{0.0, 3.9,$   
622  $5.2, 9.2, 13.0, 15.8, 18.5\}$  ms for TE = 90 ms and 105 ms; gradient separation  $\Delta = \{0.0, 27.8, 29.0,$   
623  $33.0, 28.7, 31.8, 34.7\}$  ms for TE = 75 ms and  $\Delta = \{0.0, 27.8, 29.0, 33.0, 37.0, 39.6, 42.3\}$  ms for  
624 TE = 90 ms and TE = 105 ms.

625

626 dMRI post-processing consisted of slice-wise Python MP-PCA denoising (kernel:  $5 \times 5$ )<sup>63</sup>;  
627 MRTrix3 Gibbs unringing<sup>64</sup>; motion correction via affine co-registration<sup>67</sup>; FSL distortion  
628 correction<sup>68</sup> (1.5T data only). An experienced radiologists (R.P.L.) segmented tumours on the T2-  
629 w scan, enabling per-patient tumour volume computation. Afterwards, we warped the tumour mask  
630 to dMRI using ANTs<sup>69</sup> non-linear co-registration, and fitted the 5 dMRI models, fixing again  $f_V$   
631 and  $T2_T$  to previously computed values<sup>65</sup> (fitting bounds:  $[0; 1]$  for  $f_V$ ;  $[20; 140]$  ms for  $T2_T$ ;  $[0;$   
632  $1]$  for  $f_I$ ;  $[0.8; 3.0]$   $\mu\text{m}^2 \text{ms}^{-1}$  for  $D_{0,I}$ ;  $[8; 40]$   $\mu\text{m}$  for  $vCS$ ;  $[0.8; 3.0]$   $\mu\text{m}^2 \text{ms}^{-1}$  for  $D_{E,\infty}$  in models  
633 *Diff-in-ex* and *Diff-in-exTD*, and  $[1.75; 3.0]$   $\mu\text{m}^2 \text{ms}^{-1}$  in models *Diff-in-exFast* and *Diff-in-*  
634 *exTDFast*;  $[0; 10]$   $\mu\text{m}^2$  for  $\beta$  in models *Diff-in-ex-TD* and *Diff-in-exTDFast*).

635

636 We fitted the 5 dMRI models i) on images acquired at a b-value  $b > 100$  s/mm<sup>2</sup>, to suppress  
637 vascular signals (*fitting to the whole image set*); ii) to  $b > 900$  s/mm<sup>2</sup> images, to also minimize  
638 extra-cellular contributions (*high b-value fitting*). For scans performed on the 1.5T Siemens  
639 system: i) we used  $\Delta_{1,2} + \delta_2$  in place of  $\Delta$  in Eq. 6 (Fig. S10B), ii) we replaced Eq. 4 with a  
640 numerical implementation of restricted diffusion within spheres, based on Radial Basis Function  
641 interpolation of synthetic signals generated for DW-TRSE with Monte Carlo simulations<sup>70</sup>.

642

643 For both scanners, we also computed ADC and excess kurtosis  $K$  by fitting Eq. 10 on  $b > 100$   
644  $\text{s/mm}^2$  images (shortest TE), with in-house Python code.

645

### 646 Histology

647 We performed ultrasound-guided biopsies of one liver tumour at the Barcelona Vall d'Hebron  
648 University Hospital (Spain). The biological material underwent standard processing, HE staining  
649 and digitalisation (Hamamatsu C9600-12 slide scanner; resolution:  $0.454 \mu\text{m}$ ). An experienced  
650 pathologist (S.S.) assessed the images and drew a region-of-interest (ROI) outlining the tumours.  
651 In parallel, an experienced radiologist (R.P.L.) inspected ultrasound and MR images, outlining the  
652 biopsied tumour on the latter. We processed HE data with QuPath and computed per-biopsy  
653  $vCS_{histo}$ ,  $F_{histo}$  and  $CD_{histo}$ , as previously described. Finally, we rescaled  $vCS_{histo}$  and  $CD_{histo}$ ,  
654 by multiplying  $vCS_{histo}$  from image processing by 1.503 ( $1.503 = 1.1806 \times 1.2732$ , where 1.2732  
655 accounts for biases from 2D sectioning, and 1.1806 accounts for a plausible tissue shrinkage of  
656 15.3% following fixation, dehydration, clearing and paraffin embedding<sup>56</sup>). The final  $CD_{histo}$   
657 estimate was instead 1.3938 times smaller than the value derived from direct image processing,  
658 since  $1 \text{ mm}^2$  of shrunk tissue corresponds to  $1.1806 \times 1.1806 \text{ mm}^2 = 1.3938 \text{ mm}^2$  of unprocessed  
659 tissue for a shrinkage factor of 15.3%<sup>56</sup>.

660

### 661 **Statistical analyses**

#### 662 dMRI model selection

663 We carried out model selection independently for each of the two fitting strategies. The MRI-  
664 histology *Total Correlation Score* (TCS) selects the model providing the highest Pearson's  
665 correlation between  $vCS_{MRI}$  and  $vCS_{histo}$ , and between  $F_{MRI}$  and  $F_{histo}$ . It is defined as

666

$$667 \text{TCS} = r(vCS_{MRI}, vCS_{histo}) + r(F_{MRI}, F_{histo}), (13)$$

668

669 where  $r(vCS_{MRI}, vCS_{histo})$  and  $r(F_{MRI}, F_{histo})$  are the correlation coefficients of  $vCS_{MRI}$  and  
670  $F_{MRI}$  with histological  $vCS_{histo}$  and  $F_{histo}$ . The correlation between  $CD_{MRI}$  and  $CD_{histo}$  was not  
671 included in Eq. 13 since  $CD_{MRI}$  is determined analytically from  $vCS_{MRI}$  and  $F_{MRI}$ . For TCS  
672 computation, we pooled together mouse and human data ( $N = 25$ ).

673

674 We also performed model selection using a *Histology Fidelity Criterion* (HFC), and popular  
675 *Bayesian Information Criterion* (BIC)<sup>33,34</sup>. HFC rewards the models providing the best accuracy

676 in the numerical estimation of histological cell size and intra-cellular fraction estimation, i.e.,  
677 minimising

678

$$679 \quad \text{HFC} = \frac{|vCS_{MRI} - vCS_{histo}|}{vCS_{histo}} + \frac{|F_{MRI} - F_{histo}|}{F_{histo}}. \quad (14)$$

680

681 Information on  $CD_{MRI}$  and  $CD_{histo}$  was not included in Eq. 14 since  $CD_{MRI}$  is not a degree of  
682 freedom of the dMRI models (it is determined analytically from  $vCS_{MRI}$  and  $F_{MRI}$ ). BIC selects  
683 the model providing the best goodness of fit, penalising complexity, by minimising

684

$$685 \quad \text{BIC} = P \ln(N) - \ln(\lambda). \quad (15)$$

686

687  $\lambda$  is the maximised likelihood, and  $P/N$  are the number of model parameters/signal measurements.  
688 We performed BIC selection voxel-wise, followed by majority voting across voxels.

689

### 690 Simulated dMRI model selection

691 We synthesised signals via Monte Carlo diffusion random walks for each of the three dMRI  
692 protocols of this study, using the MCDC simulator<sup>70</sup>. We seeded walkers in a substrate made of  
693 spherical cells of identical diameter<sup>6,19,22,23</sup> (Fig. S5), controlling the intra-sphere fraction  $F$  by  
694 adding gaps of increasing size in-between abutting spheres, packed in an ideal cubic lattice. We  
695 probed four  $F$  values (0.197, 0.323, 0.406, 0.523) and four sphere diameters for each  $F$  (8, 16, 22  
696 and 30  $\mu\text{m}$ ). We varied intra-/extra-sphere diffusivities ( $10 \times 10$  values;  $[0.8; 2.6] \mu\text{m}^2 \text{ms}^{-1}$  for the  
697 *ex vivo* protocol and  $[0.8; 3.0] \mu\text{m}^2 \text{ms}^{-1}$  for *in vivo* protocols), for a total of 1600 synthetic voxels.  
698 We corrupted synthetic signals with Rician noise ( $b = 0$  signal-to-noise ratio: 30), and performed  
699 model selection according to TCS, HFC and BIC.

700

### 701 dMRI-histology correlation analysis

702 We computed mean and standard deviation of all metrics i) within the mouse liver samples, ii)  
703 within a mask containing all liver tumours in patients, iii) within the biopsied patients' tumours.  
704 We pooled together metrics from mice and patients to calculate Pearson's correlation coefficients  
705  $r$ . In doing so, ADC was normalised to the ADC of the PBS solutions in mice and to the free water  
706 diffusivity in patients ( $3.0 \mu\text{m}^2 \text{ms}^{-1}$  at 37 °C), given the difference in temperature.

707

### 708 Response assessment in immunotherapy

709 We studied mean values of *in vivo* baseline dMRI metrics within liver tumours to assess whether  
710 these could stratify the probability of progression under immunotherapy, measured by PFS (N =  
711 30). Firstly, we performed the stratification after binarising all MRI metrics as lower/higher than  
712 the median of the cohort, creating two groups. We evaluated group-wise survival curves with the  
713 Kaplan-Meier estimator, and compared them with a log-rank test. We also fitted a proportional  
714 hazard Cox regression, where the binarised MRI metric was the only regressor. Secondly, we  
715 stratified PFS without binarising MRI metrics. We fitted a proportional hazard Cox model using  
716 each continuous dMRI metric as the only regressor (in the form of a z-score), and then fitted the  
717 statistical model again, including age, sex and total baseline tumour volume as confounding  
718 factors. We performed all analyses in Python, using *lifelines*.

719

## 720 **Acknowledgments**

721 We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and  
722 IT teams at the Vall d’Hebron University Hospital and at the Vall d’Hebron Institute of Oncology  
723 in Barcelona (Spain), without whom this study would not have been possible. We are also thankful  
724 to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their  
725 assistance, and to past and present members of the Radiomics group for useful discussion and  
726 advice. Finally, we would like to express our sincere gratitude to all patients and their families for  
727 dedicating their time to research. VHIO would like to acknowledge: the State Agency for Research  
728 (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo  
729 Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing  
730 research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya  
731 for their support on this research. This research has been supported by PREDICT, sponsored by  
732 AstraZeneca. This study has been co-funded by the European Regional Development  
733 Fund/European Social Fund 'A way to make Europe' (to R.P.L.), and by the Comprehensive  
734 Program of Cancer Immunotherapy & Immunology (CAIMI), funded by the Banco Bilbao  
735 Vizcaya Argentaria Foundation (FBBVA, grant 89/2017). R.P.L is supported by the  
736 “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate  
737 Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERRO  
738 Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud  
739 Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra  
740 el Cancer (AECC) (PRYCO211023SERR) and the Generitat de Catalunya Agency for  
741 Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). The  
742 project that gave rise to these results received the support of a fellowship from “la Caixa”  
743 Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G.,  
744 A.V., and A.G.) and “LCF/BQ/PI20/11760033” (funding I.C.S). I.C.S. also receives the support  
745 of the European Union’s Horizon 2020 research and innovation programme under the Marie  
746 Sklodowska-Curie grant agreement No 847648. This research has received support from the  
747 Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the

748 Department of Business and Knowledge of the Government of Catalonia, and the support from the  
749 Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP  
750 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship  
751 MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586).

752

### 753 **Author information**

754 Francesco Grussu and Raquel Perez-Lopez are joint corresponding authors.

755

### 756 **Authors and affiliations**

757 *Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus,*  
758 *Barcelona, Spain.* Francesco Grussu, Kinga Bernatowicz, Irene Casanova-Salas, Ignasi Barba,  
759 Sara Simonetti, Garazi Serna, Athanasios Grigoriou, Anna Voronova, Rodrigo Toledo, Paolo  
760 Nuciforo & Raquel Perez-Lopez.

761 *Cardiff University, Cardiff, United Kingdom.* Marco Palombo.

762 *University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain.* Ignasi Barba.

763 *Department of Biomedicine, Faculty of Medicine and Health Sciences, University of Barcelona,*  
764 *Barcelona, Spain.* Athanasios Grigoriou & Anna Voronova.

765 *PET/MR Unit, CETIR-ASCIREs, Barcelona, Spain.* Valezka Garay.

766 *Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.* Juan Francisco  
767 Corral, Xavier Merino, Richard Mast, Núria Roson & Manuel Escobar.

768 *Institut de Diagnòstic per la Imatge (IDI), Barcelona, Spain.* Juan Francisco Corral, Xavier  
769 Merino, Richard Mast, Núria Roson & Manuel Escobar.

770 *Siemens Healthineers, Madrid, Spain.* Marta Vidorreta.

771 *GE HealthCare, Madrid, Spain.* Pablo García-Polo García.

772 *Medical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute*  
773 *of Oncology (VHIO), Barcelona, Spain.* Maria Vieito, Joaquin Mateo & Elena Garralda

774

### 775 **Contributions**

776 Conceptualization: F.G., R.P.L., K.B., M.P., E.G., R.T., P.N., J.M. Methodology: F.G., R.P.L.,  
777 K.B., M.P., A.G. Investigation: F.G., R.P.L., K.B., I.C.S., I.B., S.S., G.S., A.G., V.G., J.F.C., X.M.,  
778 R.M., N.R., M.E., M.Vie., R.T., P.N., J.M., E.G. Resources: R.P.L., F.G., P.N., J.M., E.G., N.R.,  
779 M.E., V.G., M.Vid., P.G.P.G, I.B. Formal analysis: F.G. Visualization: F.G. Software: F.G., K.B.,  
780 A.G. Data curation: F.G., R.P.L., K.B., A.V., G.S., I.C.S., A.G. Project administration: F.G.,  
781 R.P.L., K.B., E.G., P.N., R.T., J.M., I.C.S. Funding acquisition: R.P.L., E.G., R.T., P.N., J.M.,

782 F.G., K.B., I.C.S. Supervision: F.G., R.P.L., E.G., R.T., P.N., J.M. Writing—original draft: F.G.,  
783 R.P.L., K.B., M.P. Writing—review & editing: all authors

#### 784 **Corresponding authors**

785 Correspondence to Francesco Grussu or Raquel Perez-Lopez.

786

#### 787 **Ethics declarations**

##### 788 **Competing interests**

789 This study received funding from AstraZeneca. M.Vid. works for Siemens Healthineers. P.G.P.G.  
790 works for GE HealthCare. K.B. worked as a researcher at the Vall d’Hebron Institute of Oncology  
791 (Barcelona), and is now an employee of AstraZeneca. AstraZeneca, Siemens and General Electric  
792 did not influence the acquisition and analysis of the data, the interpretation of the results, or the  
793 decision to submit the manuscript in its current form for publication.

##### 794 **Ethics**

795 All experimental protocols in animals were approved and monitored by the Vall d’Hebron Institute  
796 of Research Animal Experimentation Ethics Committee (CEEA; registration number 68/20) in  
797 accordance with relevant local and EU regulations. The imaging study in cancer patients was  
798 approved by the Vall d’Hebron University Hospital Ethics committee (PR(AG)29/2020),  
799 Barcelona, Spain. Patients provided informed written consent to participate in the study.

800

#### 801 **Supplementary Information**

802 This article includes Supplementary Figure S1 to S17 and Supplementary Tables S1 to S5.

803

#### 804 **References**

805

- 806 1. Weiskopf, N., Edwards, L. J., Helms, G., Mohammadi, S. & Kirilina, E. Quantitative magnetic  
807 resonance imaging of brain anatomy and in vivo histology. *Nature Reviews Physics* **3**, 570–588  
808 (2021).
- 809 2. Jarrett, A. M. *et al.* Quantitative magnetic resonance imaging and tumor forecasting of breast cancer  
810 patients in the community setting. *Nat. Protoc.* **16**, 5309–5338 (2021).
- 811 3. Kiselev, V. G. Fundamentals of diffusion MRI physics. *NMR Biomed.* **30**, (2017).
- 812 4. Novikov, D. S., Fieremans, E., Jespersen, S. N. & Kiselev, V. G. Quantifying brain microstructure  
813 with diffusion MRI: Theory and parameter estimation. *NMR Biomed.* **32**, e3998 (2019).
- 814 5. Le Bihan, D. Looking into the functional architecture of the brain with diffusion MRI. *Nat. Rev.*  
815 *Neurosci.* **4**, 469–480 (2003).
- 816 6. Panagiotaki, E. *et al.* Noninvasive quantification of solid tumor microstructure using VERDICT  
817 MRI. *Cancer Res.* **74**, 1902–1912 (2014).

- 818 7. Veraart, J. *et al.* Noninvasive quantification of axon radii using diffusion MRI. *Elife* **9**, e49855  
819 (2020).
- 820 8. Cohen-Adad, J. *et al.* Generic acquisition protocol for quantitative MRI of the spinal cord. *Nat.*  
821 *Protoc.* **16**, 4611–4632 (2021).
- 822 9. Baxter, G. C., Graves, M. J., Gilbert, F. J. & Patterson, A. J. A Meta-analysis of the Diagnostic  
823 Performance of Diffusion MRI for Breast Lesion Characterization. *Radiology* **291**, 632–641 (2019).
- 824 10. Donato, H., França, M., Candelária, I. & Caseiro-Alves, F. Liver MRI: From basic protocol to  
825 advanced techniques. *Eur. J. Radiol.* **93**, 30–39 (2017).
- 826 11. Tapper, E. B. & Lok, A. S.-F. Use of Liver Imaging and Biopsy in Clinical Practice. *N. Engl. J.*  
827 *Med.* **377**, 756–768 (2017).
- 828 12. Tsilimigras, D. I. *et al.* Liver metastases. *Nat Rev Dis Primers* **7**, 27 (2021).
- 829 13. Eisenhauer, E. A. *et al.* New response evaluation criteria in solid tumours: revised RECIST  
830 guideline (version 1.1). *Eur. J. Cancer* **45**, 228–247 (2009).
- 831 14. Buikhuisen, J. Y., Torang, A. & Medema, J. P. Exploring and modelling colon cancer inter-tumour  
832 heterogeneity: opportunities and challenges. *Oncogenesis* **9**, 66 (2020).
- 833 15. Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and  
834 response to immunotherapy. *Nat. Med.* **27**, 212–224 (2021).
- 835 16. Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic  
836 science to clinical practice. *Nat. Rev. Immunol.* **20**, 651–668 (2020).
- 837 17. Pilard, C. *et al.* Cancer immunotherapy: it's time to better predict patients' response. *Br. J. Cancer*  
838 **125**, 927–938 (2021).
- 839 18. O'Connor, J. P. B. *et al.* Imaging biomarker roadmap for cancer studies. *Nat. Rev. Clin. Oncol.* **14**,  
840 169–186 (2017).
- 841 19. Jiang, X., Xu, J. & Gore, J. C. Mapping hepatocyte size in vivo using temporal diffusion  
842 spectroscopy MRI. *Magn. Reson. Med.* **84**, 2671–2683 (2020).
- 843 20. Panagiotaki, E. *et al.* Microstructural Characterization of Normal and Malignant Human Prostate  
844 Tissue With Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours Magnetic  
845 Resonance Imaging. *Invest. Radiol.* **50**, 218 (2015).
- 846 21. Gardier, R. *et al.* Cellular Exchange Imaging (CEXI): Evaluation of a diffusion model including  
847 water exchange in cells using numerical phantoms of permeable spheres. *Magn. Reson. Med.* (2023)  
848 doi:10.1002/mrm.29720.
- 849 22. Hoffmann, E. *et al.* Profiling specific cell populations within the inflammatory tumor  
850 microenvironment by oscillating-gradient diffusion-weighted MRI. *J Immunother Cancer* **11**,  
851 e006092 (2023).
- 852 23. Jiang, X. *et al.* MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. *J*  
853 *Immunother Cancer* **8**, (2020).
- 854 24. Ye, Z. *et al.* Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI)  
855 and Machine Learning Improves Detection and Classification of Glioblastoma Pathology. *Clin.*  
856 *Cancer Res.* **26**, 5388–5399 (2020).




- 857 25. Howard, A. F. *et al.* Joint modelling of diffusion MRI and microscopy. *Neuroimage* **201**, 116014  
858 (2019).
- 859 26. Novikov, D. S., Kiselev, V. G. & Jespersen, S. N. On modeling. *Magn. Reson. Med.* **79**, 3172–3193  
860 (2018).
- 861 27. Xu, J. *et al.* Diffusion time dependency of extracellular diffusion. *Magn. Reson. Med.* **89**, 2432–  
862 2440 (2023).
- 863 28. Neuman, C. H. Spin echo of spins diffusing in a bounded medium. *J. Chem. Phys.* **60**, 4508–4511  
864 (1974).
- 865 29. Conlin, C. C. *et al.* Improved Characterization of Diffusion in Normal and Cancerous Prostate  
866 Tissue Through Optimization of Multicompartmental Signal Models. *J. Magn. Reson. Imaging* **53**,  
867 628–639 (2021).
- 868 30. Jensen, J. H., Helpert, J. A., Ramani, A. & Lu, H. Diffusional kurtosis imaging: the quantification  
869 of non-gaussian water diffusion by means of magnetic resonance imaging. *in Medicine: An ...*  
870 (2005).
- 871 31. Hectors, S. J. *et al.* Advanced Diffusion-weighted Imaging Modeling for Prostate Cancer  
872 Characterization: Correlation with Quantitative Histopathologic Tumor Tissue Composition-A  
873 Hypothesis-generating Study. *Radiology* **286**, 918–928 (2018).
- 874 32. Bankhead, P. *et al.* QuPath: Open source software for digital pathology image analysis. *Sci. Rep.* **7**,  
875 16878 (2017).
- 876 33. Schwarz, G. Estimating the Dimension of a Model. *aos* **6**, 461–464 (1978).
- 877 34. Panagiotaki, E. *et al.* Compartment models of the diffusion MR signal in brain white matter: a  
878 taxonomy and comparison. *Neuroimage* **59**, 2241–2254 (2012).
- 879 35. Ferizi, U. *et al.* A ranking of diffusion MRI compartment models with in vivo human brain data.  
880 *Magn. Reson. Med.* **72**, 1785–1792 (2014).
- 881 36. Palombo, M. *et al.* Joint estimation of relaxation and diffusion tissue parameters for prostate cancer  
882 with relaxation-VERDICT MRI. *Sci. Rep.* **13**, 2999 (2023).
- 883 37. Jiang, X., Devan, S. P., Xie, J., Gore, J. C. & Xu, J. Improving MR cell size imaging by inclusion of  
884 transcytolemmal water exchange. *NMR Biomed.* **35**, e4799 (2022).
- 885 38. Rosenkrantz, A. B. *et al.* Assessment of hepatocellular carcinoma using apparent diffusion  
886 coefficient and diffusion kurtosis indices: preliminary experience in fresh liver explants. *Magn.*  
887 *Reson. Imaging* **30**, 1534–1540 (2012).
- 888 39. Tang, W.-J. *et al.* Evaluation of the Effects of Anti-PD-1 Therapy on Triple-Negative Breast Cancer  
889 in Mice by Diffusion Kurtosis Imaging and Dynamic Contrast-Enhanced Imaging. *J. Magn. Reson.*  
890 *Imaging* **56**, 1912–1923 (2022).
- 891 40. Martin, N. C. *et al.* Functional analysis of mouse hepatocytes differing in DNA content: volume,  
892 receptor expression, and effect of IFN $\gamma$ . *J. Cell. Physiol.* **191**, 138–144 (2002).
- 893 41. Zhou, Z., Xu, M.-J. & Gao, B. Hepatocytes: a key cell type for innate immunity. *Cell. Mol.*  
894 *Immunol.* **13**, 301–315 (2016).

- 895 42. Grussu, F. *et al.* Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion  
896 time: Insights from simulations, 9.4T imaging, and histology. *Magn. Reson. Med.* (2022)  
897 doi:10.1002/mrm.29174.
- 898 43. Morawski, M. *et al.* Developing 3D microscopy with CLARITY on human brain tissue: Towards a  
899 tool for informing and validating MRI-based histology. *Neuroimage* **182**, 417–428 (2018).
- 900 44. Jelescu, I. O., Veraart, J., Fieremans, E. & Novikov, D. S. Degeneracy in model parameter  
901 estimation for multi-compartmental diffusion in neuronal tissue. *NMR Biomed.* **29**, 33–47 (2016).
- 902 45. Nilsson, M. *et al.* Mapping prostatic microscopic anisotropy using linear and spherical b-tensor  
903 encoding: A preliminary study. *Magn. Reson. Med.* **86**, 2025–2033 (2021).
- 904 46. Fokkinga, E. *et al.* Advanced Diffusion-Weighted MRI for Cancer Microstructure Assessment in  
905 Body Imaging, and Its Relationship With Histology. *J. Magn. Reson. Imaging* (2023)  
906 doi:10.1002/jmri.29144.
- 907 47. Jensen, J. H., Russell Glenn, G. & Helpert, J. A. Fiber ball imaging. *Neuroimage* **124**, 824–833  
908 (2016).
- 909 48. McKinnon, E. T., Helpert, J. A. & Jensen, J. H. Modeling white matter microstructure with fiber  
910 ball imaging. *Neuroimage* **176**, 11–21 (2018).
- 911 49. Warner, W. *et al.* Temporal Diffusion Ratio (TDR) for imaging restricted diffusion: Optimisation  
912 and pre-clinical demonstration. *Neuroimage* **269**, 119930 (2023).
- 913 50. Reynaud, O. Time-Dependent Diffusion MRI in Cancer: Tissue Modeling and Applications.  
914 *Frontiers in Physics* **5**, (2017).
- 915 51. Serrablo, A. *et al.* Impact of novel histopathological factors on the outcomes of liver surgery for  
916 colorectal cancer metastases. *Eur. J. Surg. Oncol.* **42**, 1268–1277 (2016).
- 917 52. Nuciforo, P. *et al.* A predictive model of pathologic response based on tumor cellularity and tumor-  
918 infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual  
919 HER2 blockade. *Ann. Oncol.* **29**, 170–177 (2018).
- 920 53. Gentile, D. *et al.* Pathologic response and residual tumor cellularity after neo-adjuvant  
921 chemotherapy predict prognosis in breast cancer patients. *Breast* **69**, 323–329 (2023).
- 922 54. Lee, H.-H., Papaioannou, A., Novikov, D. S. & Fieremans, E. In vivo observation and biophysical  
923 interpretation of time-dependent diffusion in human cortical gray matter. *Neuroimage* **222**, 117054  
924 (2020).
- 925 55. Fortin, J.-P. *et al.* Harmonization of multi-site diffusion tensor imaging data. *Neuroimage* **161**, 149–  
926 170 (2017).
- 927 56. Boonstra, H., Oosterhuis, J. W., Oosterhuis, A. M. & Fleuren, G. J. Cervical tissue shrinkage by  
928 formaldehyde fixation, paraffin wax embedding, section cutting and mounting. *Virchows Arch. A*  
929 *Pathol. Anat. Histopathol.* **402**, 195–201 (1983).
- 930 57. Xu, J. *et al.* MRI-cytometry: Mapping nonparametric cell size distributions using diffusion MRI.  
931 *Magn. Reson. Med.* **85**, 748–761 (2021).
- 932 58. Xu, J. *et al.* Magnetic resonance imaging of mean cell size in human breast tumors. *Magn. Reson.*  
933 *Med.* **83**, 2002–2014 (2020).

- 934 59. Reynaud, O. *et al.* Pulsed and oscillating gradient MRI for assessment of cell size and extracellular  
935 space (POMACE) in mouse gliomas. *NMR Biomed.* **29**, 1350–1363 (2016).
- 936 60. Le Bihan, D. *et al.* MR imaging of intravoxel incoherent motions: application to diffusion and  
937 perfusion in neurologic disorders. *Radiology* **161**, 401–407 (1986).
- 938 61. Li, Y. T. *et al.* Liver intravoxel incoherent motion (IVIM) magnetic resonance imaging: a  
939 comprehensive review of published data on normal values and applications for fibrosis and tumor  
940 evaluation. *Quant. Imaging Med. Surg.* **7**, 59–78 (2017).
- 941 62. Balinov, B., Jonsson, B., Linse, P. & Soderman, O. The NMR Self-Diffusion Method Applied to  
942 Restricted Diffusion. Simulation of Echo Attenuation from Molecules in Spheres and between  
943 Planes. *J. Magn. Reson. A* **104**, 17–25 (1993).
- 944 63. Veraart, J. *et al.* Denoising of diffusion MRI using random matrix theory. *Neuroimage* **142**, 394–  
945 406 (2016).
- 946 64. Kellner, E., Dhital, B., Kiselev, V. G. & Reiser, M. Gibbs-ringing artifact removal based on local  
947 subvoxel-shifts. *Magn. Reson. Med.* **76**, 1574–1581 (2016).
- 948 65. Jerome, N. P. *et al.* Extended T2-IVIM model for correction of TE dependence of pseudo-diffusion  
949 volume fraction in clinical diffusion-weighted magnetic resonance imaging. *Phys. Med. Biol.* **61**,  
950 N667–N680 (2016).
- 951 66. Garyfallidis, E. *et al.* Dipy, a library for the analysis of diffusion MRI data. *Front. Neuroinform.* **8**, 8  
952 (2014).
- 953 67. Ourselin, S., Roche, A., Subsol, G., Pennec, X. & Ayache, N. Reconstructing a 3D structure from  
954 serial histological sections. *Image Vis. Comput.* **19**, 25–31 (2001).
- 955 68. Andersson, J. L. R., Skare, S. & Ashburner, J. How to correct susceptibility distortions in spin-echo  
956 echo-planar images: application to diffusion tensor imaging. *Neuroimage* **20**, 870–888 (2003).
- 957 69. Avants, B. B., Epstein, C. L., Grossman, M. & Gee, J. C. Symmetric diffeomorphic image  
958 registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative  
959 brain. *Med. Image Anal.* **12**, 26–41 (2008).
- 960 70. Rafael-Patino, J. *et al.* Robust Monte-Carlo Simulations in Diffusion-MRI: Effect of the Substrate  
961 Complexity and Parameter Choice on the Reproducibility of Results. *Front. Neuroinform.* **14**, 8  
962 (2020).
- 963
- 964
- 965
- 966
- 967
- 968
- 969


970 **Figures**



971


972 **Fig. 1. Illustration of the liver MRI and histology data used in the study.** Our data set consisted  
 973 of preclinical and clinical data. The preclinical data encompasses dMRI scans of seven fixed livers  
 974 from mice (six implanted with tissue from biopsies of patients suffering from prostate cancer; one  
 975 without any implantation). We scanned the livers *ex vivo* on a 9.4T system, and obtained HE  
 976 histological sections at known position. The clinical data includes *in vivo* liver dMRI scans  
 977 performed on 33 patients suffering from advanced liver tumours. Scans were performed on clinical  
 978 1.5T and 3T MRI systems. For 18 patients, HE-stained material from a biopsy taken from one of  
 979 the imaged liver tumours was also available. 30 out of 33 patients effectively participated in a  
 980 phase I immunotherapy trial, and clinical outcome was available as PFS. We used a total sample  
 981 size of N = 25 for dMRI model design and of N = 30 for response assessment. In the figure, PC  
 982 standard fort prostate cancer and HCC for hepatocellular carcinoma.

### (A) dMRI signal models



Models with no assumption on which of intra-/extra-cellular ADC is higher


• *Diff-in-exTD* • *Diff-in-ex*



Models with higher extra-cellular ADC than intra-cellular ADC

• *Diff-in-exTDFast* • *Diff-in-exFast*  
• *Diff-in*

### (B) Study overview



983

984

985

986

987

988

989

990

991

992

**Fig. 2. Description of the dMRI signal models and study overview.** (A), top: cartoon illustrating the two families of dMRI models considered in this study, consisting of 1) models with no assumption of which of intra-/extra-cellular ADC is higher, and 2) models where the extra-cellular ADC is hypothesised to be higher than the intra-cellular ADC. (B), bottom: study overview. We analysed dMRI data from fixed mouse livers (preclinical data) and from cancer patients imaged *in vivo* (clinical data) to derive estimates of intra-cellular fraction and of cell size. In parallel, we processed histological material from the same tissues (whole-liver sections for the preclinical mouse data; biopsies from one of the imaged tumours for the clinical data), and derived the histological counterparts of such dMRI metrics. We compared dMRI and histological cell size and


993 intra-cellular fraction to select the dMRI model featuring the best fidelity to histology. The utility  
994 of the model was then demonstrated in immunotherapy response assessment *in vivo*. In Fig. 2,  
995 pictures from Servier Medical Art have been used. Servier Medical Art by Servier is licensed under  
996 a Creative Commons Attribution 3.0 Unported License  
997 (<https://creativecommons.org/licenses/by/3.0/>).

998

999

1000

1001



1002

1003

1004

1005

1006

1007

1008

1009

1010


1011

1012

1013

1014

**Fig. 3. Biophysical dMRI signal model selection based on the MRI-histology Total Correlation Score (TCS).** (A): panel summarising the salient differences between the biophysical dMRI models compared in this study. Models can be divided in two families, i.e.: i) models where it is hypothesised that the extra-cellular ADC is higher than the intra-cellular ADC, and ii) models with no hypothesis on which, between intra-/extra-cellular ADC is higher. Violet shades are used for the first family (models *Diff-in*, *Diff-in-exFast* and *Diff-in-exTDFast*), while orange shades for the second family (models *Diff-in-ex* and *Diff-in-exTD*). (B): values of TCS for all models, as obtained by fitting them on high b-value images ( $b > 1800$  s/mm<sup>2</sup> in the fixed mouse livers;  $b > 900$  s/mm<sup>2</sup> *in vivo*). We performed model selection using a sample size of  $N = 25$  (see Fig. 1). In Fig. 3, pictures from Servier Medical Art have been used. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (<https://creativecommons.org/licenses/by/3.0/>).



1015

1016

1017

1018

1019

1020

1021

1022

1023

1024


**Fig. 4. Maps from the selected dMRI model *Diff-in* with their histological counterparts in the fixed mouse livers scanned at 9.4T *ex vivo*.** The figure reports MRI and histology data for 3 specimens, representative of the 3 microstructural phenotypes observed in our *ex vivo* data set, namely: normal liver structures (*Control* case); a proliferative process, characterized by infiltration of small cells (*Pat<sub>infl</sub>* case); necrosis and inflammation (*Pat<sub>nec</sub>* case). For all specimens, the following is shown. **(A)**, *top left*: a high-resolution T2-w anatomical scan is shown next to the corresponding HE section, with histological details. **(B)**, *bottom left*: histological maps warped to the dMRI space (intra-cellular patch area fraction  $F_{histo}$ ; volume-weighted mean cell size index  $vCS_{histo}$ ; cell density per unit patch area  $CD_{histo}$ ). **(D)**, *bottom right*: dMRI maps  $F_{MRI}$ ,  $vCS_{MRI}$

1025 and  $CD_{MRI}$  from the selected dMRI signal model (model *Diff-in*, fitted to high  $b$ -value images, i.e.,  
 1026  $b > 1800 \text{ s/mm}^2$ ).

1027

1028

1029




1030

1031 **Fig. 5. Examples of maps from the proposed dMRI model *Diff-in* in liver tumours of patients**  
 1032 **scanned at 1.5T and 3T *in vivo*, with co-localised biopsies. MRI maps are shown in a biopsied**  
 1033 **liver tumour in two patients for each MRI scanner, arranged along rows. (A): examples of slices**  
 1034 **from the high-resolution anatomical T2-w image and from a high b-value image, with biopsied**  
 1035 **tumour outlined. (C): maps from the selected model (*Diff-in*, fitted to high b-value images  $b > 900$**   
 1036  **$\text{s/mm}^2$ ). From left to right: intra-cellular signal fraction  $F_{MRI}$ ; volume-weighted mean cell size**  
 1037 **index  $vCS_{MRI}$ ; cell density per unit volume  $CD_{MRI}$ . (C): histological details from the HE-stained**  
 1038 **biopsy. For the 1.5T Siemens scanner (first and second rows from top) we report: patient 6**  
 1039 **(primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the**  
 1040 **3T GE scanner (third and fourth rows from top) we report: patient 24 (primary hepatocellular**  
 1041 **carcinoma (HCC)) and patient 30 (liver metastases from breast cancer).**

1042





1043

1044

1045

1046

1047

1048

1049


1050

1051

**Fig. 6. Immunotherapy response assessment based on metrics from the proposed model *Diff-in* within liver tumours at baseline.** This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of  $F$ ,  $vCS$  and  $CD$  within liver tumours at baseline (i.e., before starting immunotherapy), as obtained by fitting model *Diff-in* at high b-value. *Left*: Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on baseline  $F$  (panel A),  $vCS$  (panel C) and  $CD$  (panel D) (lower/higher than the sample median). The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate

1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061

and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. *Right*: results from univariate Cox regression where the baseline  $F$  (panel B),  $vCS$  (panel D) and  $CD$  (panel F) is a continuous predictor of the survival. The panel shows how changes in baseline  $F$ ,  $vCS$  and  $CD$  modulate the survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis shows  $1 - p$ , with  $p$  being the probability of progression, while the x-axis shows the time to progression (in days). We performed the response assessment using a sample size of  $N = 30$  (Fig. 1).



1062  
1063  
1064  
1065  
1066  
1067

**Fig. 7. Immunotherapy response assessment based on mean  $ADC$  and kurtosis  $K$  within liver tumours at baseline.** This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of  $ADC$  and  $K$  within liver tumours at baseline (i.e., before starting immunotherapy). *Left*: Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on baseline  $ADC$  (panel A) and  $K$  (panel C) (lower/higher than the sample median).

1068 The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox  
 1069 regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate  
 1070 and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and  
 1071 Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. *Right*: results from  
 1072 univariate Cox regression where the baseline *ADC* (panel B) and *K* (panel D) is a continuous  
 1073 predictor of the survival. The panel shows how changes in baseline *ADC* and *K* modulate the  
 1074 survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with  
 1075 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis shows  $1$   
 1076  $- p$ , with  $p$  being the probability of progression, while the x-axis shows the time to progression (in  
 1077 days). We performed the response assessment using a sample size of  $N = 30$  (Fig. 1).

1078

1079 **Tables**

1080 **Table 1. Correlation between dMRI metrics and histological metrics.** The table reports  
 1081 Pearson’s correlation coefficients  $r$  and corresponding p-values  $p$  of dMRI metrics  $F_{MRI}$  (intra-  
 1082 cellular fraction),  $vCS_{MRI}$  (volume-weighted cell size index) and  $CD_{MRI}$  (cell density per unit  
 1083 volume) with their histological pairs ( $F_{histo}$ ,  $vCS_{histo}$  and  $CD_{histo}$  respectively) for the selected  
 1084 dMRI model (*Diff-in*, fitted to high b-value images). The table also reports correlation coefficients  
 1085 between routine ADC and *K* from DKI and each of  $F_{histo}$ ,  $vCS_{histo}$  and  $CD_{histo}$ . The sample size  
 1086 was  $N = 25$ , so that  $p < 0.05$  if  $|r| > 0.3961$ . When  $p < 0.05$ , grey shadowing is used.

dMRI technique	Histology $F_{histo}$	Histology $vCS_{histo}$	Histology $CD_{histo}$
Model	With $F_{MRI}$ :	With $vCS_{MRI}$ :	With $CD_{MRI}$ :
<i>Diff-in</i>	$r = 0.19; p = 0.37$	$r = 0.44; p = 0.029$	$r = 0.70; p = 0.0001$
Routine	With ADC: $r = -0.28; p = 0.18$	With ADC: $r = 0.49; p = 0.014$	With ADC: $r = -0.47; p = 0.017$
DKI	With <i>K</i> : $r = 0.40; p = 0.048$	With <i>K</i> : $r = -0.31; p = 0.13$	With <i>K</i> : $r = 0.43; p = 0.033$

1087

## Supplementary Information for

# Histology-informed liver diffusion MRI: biophysical model design and demonstration in cancer immunotherapy

Francesco Grussu\*, Kinga Bernatowicz, Marco Palombo, Irene Casanova-Salas, Ignasi Barba, Sara Simonetti, Garazi Serna, Athanasios Grigoriou, Anna Voronova, Valezka Garay, Juan Francisco Corral, Marta Vidorreta, Pablo García-Polo García, Xavier Merino, Richard Mast, Núria Roson, Manuel Escobar, Maria Vieito, Rodrigo Toledo, Paolo Nuciforo, Joaquin Mateo, Elena Garralda, Raquel Perez-Lopez\*

\*Corresponding authors: Francesco Grussu, email: [fgrussu@vhio.net](mailto:fgrussu@vhio.net), Raquel Perez-Lopez, email: [rperez@vhio.net](mailto:rperez@vhio.net)

### Table of contents


- Supplementary Fig. S1:** radiological-histological co-localisation of the *ex vivo* mouse liver data.
- Supplementary Fig. S2:** MRI-histology Total Correlation Score (TCS) for biophysical dMRI model selection, as obtained when fitting dMRI signal models on the whole image set.
- Supplementary Fig. S3:** biophysical dMRI signal model selection based on BIC and HFC criteria.
- Supplementary Fig. S4:** biophysical model selection across different MRI scanners and data subsets.
- Supplementary Fig. S5:** environments used to generate synthetic dMRI signals in computer simulations.
- Supplementary Fig. S6:** MRI-histology correlations for models with no assumptions on which is larger between intra-cellular and extra-cellular ADC.
- Supplementary Fig. S7:** MRI-histology correlations for models where the extra-cellular ADC is constrained to be larger than the intra-cellular ADC.
- Supplementary Fig. S8:** standard diffusion MRI metrics in fixed mouse livers *ex vivo*.
- Supplementary Fig. S9:** key parametric maps of the *Diff-in-exFast* model on *ex vivo* mouse livers.
- Supplementary Fig. S10:** diffusivity metrics from biophysical MRI models in fixed *ex vivo* mouse livers.
- Supplementary Fig. S11:** standard diffusion MRI metrics in patients *in vivo*.
- Supplementary Fig. S12:** key parametric maps of the *Diff-in-exFast* model in patients *in vivo*.
- Supplementary Fig. S13:** diffusivity metrics from biophysical MRI models in patients *in vivo*.
- Supplementary Fig. S14:** immunotherapy response assessment based on *Diff-in* cytosol diffusivity estimates.
- Supplementary Fig. S15:** immunotherapy response assessment based on vascular fraction estimates.
- Supplementary Fig. S16:** immunotherapy response assessment based on *Diff-in-exFast* MRI metrics.
- Supplementary Fig. S17:** schematic of the dMRI sequences used in this study.
- Supplementary Table S1:** results of the model selection based on the Total Correlation Score (TCS) as obtained on simulated dMRI signals.

**Supplementary Table S2:** results of the model selection based on the Histology Fidelity Criterion (HFC) as obtained on simulated dMRI signals.

**Supplementary Table S3:** results of the model selection based on the Bayesian Information Criterion (BIC) as obtained on simulated dMRI signals.


**Supplementary Table S4:** descriptive statistics of histology and MRI metrics in the fixed mouse livers.

**Supplementary Table S5:** hazard ratios obtained from Cox regression models controlling for sex, age, and baseline tumour volume.




**Fig. S1: radiological-histological co-localisation of the *ex vivo* mouse liver data.**

Illustration of the radiological-histological co-localisation on the 7 fixed mouse livers obtained from mice implanted with a biopsy from a prostate cancer patient. (A), left: illustrative slice of the high-resolution anatomical T2-weighted fast spin echo. (B), centre: hematoxylin and eosin (HE)-stained section, taken from the MRI slice shown to the left. (C), right: detail of the microstructure characterising each specimen, as assessed by an experienced pathologist (SS). Different specimens are arranged along different rows. From top to bottom: *Control*, normal liver structures (no biopsy implantation); *Pat<sub>NA1</sub>* and *Pat<sub>NA2</sub>*, normal appearing normal liver structures after prostate cancer biopsy implantation; *Pat<sub>inf1</sub>*, *Pat<sub>inf2</sub>* and *Pat<sub>inf3</sub>*: pathology following implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces); *Pat<sub>nec</sub>*, pathology following implantation, consisting of necrosis and inflammation.



**Fig. S2: MRI-histology Total Correlation Score (TCS) for biophysical dMRI model selection, as obtained when fitting dMRI signal models on the whole image set.**


Values of TCS for all models, as obtained by fitting models on the whole image set (set of images with negligible vascular signal contributions, i.e.,  $b > 1000$  s/mm<sup>2</sup> in the fixed mouse livers and  $b > 100$  s/mm<sup>2</sup> *in vivo*). We evaluated TCS for histology-informed model selection using a sample size of  $N = 25$ .



**Fig. S3: biophysical dMRI signal model selection based on BIC and HFC criteria.**


Frequency of model selection based on the *Bayesian Information Criterion* (BIC, quantifying how well a model fits the dMRI signals, penalising model complexity) and on the *Histology-fidelity Criterion* (HFC, quantifying how accurately a dMRI models estimates the intra-cellular fraction and the volume-weighted cell size as seen on histology). (A) reports results when models are fitted to the entire set of measurements with negligible vascular signal contributions ( $b > 1000$  s/mm<sup>2</sup> for suppression of PBS fluid within vessels in the fixed mouse livers;  $b > 100$  s/mm<sup>2</sup> for IVIM signal suppression *in vivo* on clinical systems), while (B) reporting results obtained when fitting models only on high  $b$ -value images ( $b > 1800$  s/mm<sup>2</sup> in the fixed mouse livers;  $b > 900$  s/mm<sup>2</sup> *in vivo*).





**Fig. S4: biophysical model selection across different MRI scanners and data subsets.**


Frequency of selection of each of 5 biophysical dMRI models on 3 MRI-histology data subsets. First column: selection on 7 fixed mouse livers scanned *ex vivo* on a preclinical 9.4T Bruker system (A and D, left); Second column: selection on 6 liver tumours imaged *in vivo* on a clinical 1.5T Siemens system (B and E, middle); Third column: selection on 12 liver tumours imaged *in vivo* on a clinical 3T GE system (C and F, right). Plots on top (A to C) refer to dMRI model fitting performed on images where the vascular signal was suppressed (“whole image set fitting”,  $b > 1000$  s/mm<sup>2</sup> for suppression of PBS fluid within vessels on the 9.4T;  $b > 100$  s/mm<sup>2</sup> for IVIM signal suppression on clinical systems). Plots to the bottom (D to F) refer to dMRI model fitting performed on images where both vascular and extra-cellular, extra-vascular signals were suppressed (“high b-value fitting”,  $b > 1800$  s/mm<sup>2</sup> on the 9.4T;  $b > 900$  s/mm<sup>2</sup> on clinical systems). Violet: models where extra-cellular ADC is larger than intra-cellular ADC; orange: models with no constraints on which is larger between intra-/extra-cellular ADC. The *Bayesian Information Criterion* (BIC) selects a model depending on the goodness of MRI signal fitting. The *Histology Fidelity Criterion* (HFC) selects a model depending on the overall agreement between MRI volume-weighted Cell Size ( $vCS$ ) and intra-cellular fraction ( $F$ ) with their histology counterparts.




**Fig. S5: environments used to generate synthetic dMRI signals in computer simulations.**

The synthetic environment consisted of meshed spheres of fixed diameter, representing cells, as this is a common biophysical model used in several dMRI techniques (e.g., VERDICT, IMPULSED). We used the synthetic environment to generate dMRI signals via Monte Carlo simulations for each of the 3 dMRI protocols considered in this study (the PGSE protocol used on the *ex vivo* mouse livers at 9.4T; the PGSE protocol used in patients *in vivo* at 3T; the DW TRSE protocol used in patients *in vivo* at 1.5T). Afterwards, we performed dMRI model selection on the synthetic signals, following the same procedures implemented for actual *ex vivo* and *in vivo* dMRI data. We controlled the intra-sphere fraction  $F$  by adding gaps of increasing size in-between abutting spheres packed in an ideal cubic lattice. We probed 4 different values of  $F$  (approximately equal to 0.197, 0.323, 0.406, 0.523; notice that the maximum theoretical value of  $F$  for cubic lattice packing is equal to 0.5236). For each value of  $F$ , we varied the cell diameter (8, 16, 22 and 30  $\mu\text{m}$ ), intra-sphere diffusivity (10 linearly-spaced values in the ranges  $[0.8; 2.6] \mu\text{m}^2 \text{ms}^{-1}$  and  $[0.8; 3.0] \mu\text{m}^2 \text{ms}^{-1}$  for the *ex vivo* and *in vivo* protocols respectively) and extra-sphere intrinsic diffusivity (again, 10 linearly-spaced values in the ranges  $[0.8; 2.6] \mu\text{m}^2 \text{ms}^{-1}$  and  $[0.8; 3.0] \mu\text{m}^2 \text{ms}^{-1}$  for the *ex vivo* and *in vivo* protocols respectively), generating a total of 1600 synthetic voxels. Before dMRI signal model fitting, we corrupted synthetic signal with Rician noise at a signal-to-noise ratio (SNR) of 30 on the  $b = 0$  signal  $s(b=0)$  ( $\text{SNR} = s(b=0)/\sigma$ , where  $\sigma$  is the noise standard deviation).


Model fitting on whole image set      Model fitting on high  $b$ -value images



**Fig. S6: MRI-histology correlations for models with no assumptions on which is larger between intra-cellular and extra-cellular ADC.** Matrices illustrating Pearson's correlation coefficients among all possible pairs of MRI and histology metrics. Histological metrics are: intra-cellular area fraction  $F_{histo}$ ; volume-weighted mean cell size index  $vCS_{histo}$ ; cell density per unit area  $CD_{histo}$ . MRI metrics are: apparent diffusion coefficient  $ADC$ ; apparent diffusion excess kurtosis  $K$ ; intra-cellular area fraction  $F_{MRI}$ ; volume-weighted mean cell size index  $vCS_{MRI}$ ; cell density per unit area  $CD_{MRI}$ . Metrics  $F_{MRI}$ ,  $vCS_{MRI}$  and  $CD_{MRI}$  were obtained by fitting models with no assumptions on which is larger between intra-cellular and extra-cellular ADC (*Diff-in-ex* and *Diff-in-exTD*). The 4 panels refer to models *Diff-in-ex* and *Diff-in-exTD* fitted according to 2 different strategies. Panel (A): model *Diff-in-ex* fitted on the whole set of measurements with vascular signal suppression ( $b > 100$  s/mm<sup>2</sup> *in vivo*,  $b > 1000$  s/mm<sup>2</sup> *ex vivo*); panel (B): model *Diff-in-ex* fitted on high  $b$ -value measurements ( $b > 900$  s/mm<sup>2</sup> *in vivo*,  $b > 1800$  s/mm<sup>2</sup> *ex vivo*); panel (C): model *Diff-in-exTD* fitted on the whole set of measurements with vascular signal suppression; panel (D): model *Diff-in-exTD* fitted on high  $b$ -value measurements. We calculated correlation coefficients using a sample size of  $N = 25$  (Fig. 1).




according to 2 different strategies. Panel (A): model *Diff-in* fitted on the whole set of measurements with vascular signal suppression ( $b > 100 \text{ s/mm}^2$  *in vivo*,  $b > 1000 \text{ s/mm}^2$  *ex vivo*); panel (B): model *Diff-in* fitted on high b-value measurements ( $b > 900 \text{ s/mm}^2$  *in vivo*,  $b > 1800 \text{ s/mm}^2$  *ex vivo*); panel (C): model *Diff-in-exFast* fitted on the whole set of measurements with vascular signal suppression; panel (D): model *Diff-in-exFast* fitted on high b-value measurements; panel (E): model *Diff-in-exTDFast* fitted on the whole set of measurements with vascular signal suppression; panel (F): model *Diff-in-exTDFast* fitted on high b-value measurements. We calculated correlation coefficients using a sample size of  $N = 25$  (Fig. 1).




**Fig. S8: standard diffusion MRI metrics in fixed mouse livers *ex vivo*.**

(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): standard diffusion metrics, namely  $ADC$  (apparent diffusion coefficient) and  $K$  (apparent diffusion kurtosis excess). These metrics were obtained by fitting the standard diffusion kurtosis signal representation  $s = s_0 \exp(-b ADC + K (b ADC)^2/6)$  to the set of measurements at fixed  $TE = 45$  ms and  $\Delta = 30$  ms. From top to bottom, the figure reports maps from 3 specimens, representative of the 3 different microstructural phenotypes seen in our mouse liver data. These are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case *Pat<sub>inf1</sub>*); pathology following biopsy implantation, consisting of necrosis and inflammation (illustrated by case *Pat<sub>nec</sub>*).



**Fig. S9:** key parametric maps of the *Diff-in-exFast* model on *ex vivo* mouse livers.


(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): metrics from the *Diff-in-exFast* model fitted to the whole DW image set (b-values with negligible vascular signal contributions, i.e.,  $b > 1000$  s/mm<sup>2</sup> on fixed *ex vivo* tissue, to suppress signal from PBS-filled vessels). From left to right: intra-cellular signal fraction  $F_{MRI}$ ; volume-weighted cell size index  $vCS_{MRI}$  index; cell density per unit volume  $CD_{MRI}$ . Maps from 3 specimens are reported along different rows. The specimens are representative of the 3 different microstructural phenotypes seen in our mouse liver data. From top to bottom, these are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case *Pat<sub>inf1</sub>*); pathology following biopsy implantation, consisting of extended necrosis and inflammation (illustrated by case *Pat<sub>nec</sub>*).



**Fig. S10: diffusivity metrics from biophysical MRI models in fixed *ex vivo* mouse livers.**


(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): diffusivity metrics from biophysical model *Diff-in-exFast*, namely: intrinsic intra-cellular cytosolic diffusivity  $D_{0,l}$ ; asymptotic extra-cellular diffusion coefficient  $D_{E,\infty}$ . (C): intrinsic intra-cellular cytosolic diffusivity  $D_{0,l}$  from model *Diff-in* fitted to high b-value images ( $b > 1800$  s/mm<sup>2</sup>). Maps from 3 specimens are reported along different rows. The specimens are representative of the 3 different microstructural phenotypes seen in our mouse liver data. From top to bottom, these are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case *Pat<sub>inf1</sub>*); pathology following biopsy implantation, consisting of extended necrosis and inflammation (illustrated by case *Pat<sub>nec</sub>*).






**Fig. S11: standard diffusion MRI metrics in patients *in vivo*.**

(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): standard diffusion metrics in the biopsied tumour. Metrics are: apparent diffusion coefficient ( $ADC$ ) and apparent diffusion kurtosis excess ( $K$ ). These were obtained by fitting the standard diffusion kurtosis signal representation  $s = s_0 \exp(-b ADC + K (b ADC)^2/6)$  to the set of measurements at fixed, minimum TE and  $b > 100$  s/mm<sup>2</sup>. Maps are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (third and fourth rows from top): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).




**Fig. S12: key parametric maps of the *Diff-in-exFast* model in patients *in vivo*.**

(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): salient metrics of the *Diff-in-exFast* model fitted to the whole set of images with negligible vascular signal contributions ( $b > 100$  s/mm<sup>2</sup>). Metrics are shown in the biopsied tumour. From left to right: intra-cellular signal fraction  $F_{MRI}$ ; volume-weighted cell size index  $vCS_{MRI}$  index; cell density per unit volume  $CD_{MRI}$ . Metrics are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (first and second rows from bottom): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).




**Fig. S13: diffusivity metrics from biophysical MRI models in patients *in vivo*.**

(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): diffusivity maps from biophysical model *Diff-in-exFast* in the biopsied tumour. Metrics are: intra-cellular cytosolic diffusivity  $D_{0,I}$  and asymptotic extra-cellular diffusion coefficient  $D_{E,\infty}$ . (C): intra-cellular cytosolic diffusivity  $D_{0,I}$  for biophysical model *Diff-in* fitted being fitted only to high b-value images ( $b > 900$  s/mm<sup>2</sup>). Metrics are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (first and second rows from bottom): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).




**Fig. S14: immunotherapy response assessment based on *Diff-in* cytosol diffusivity estimates.**

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of the intrinsic intra-cellular cytosol diffusivity  $D_{0,I}$  within liver tumours at baseline (i.e., before starting immunotherapy), as obtained by fitting model *Diff-in* at high b-value. Left (panel A): Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on baseline  $D_{0,I}$  (lower or higher than the sample median). The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. Right (panel B): results from univariate Cox regression where the baseline  $D_{0,I}$  is a continuous predictor of the survival. The panel shows how changes in baseline  $D_{0,I}$  modulate the survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis shows  $1 - p$ , with  $p$  being the probability of progression, while the x-axis shows the time to progression (in days).



**Fig. S15: immunotherapy response assessment based on vascular fraction estimates.**


This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of the vascular signal fraction  $f_v$  within liver tumours at baseline (i.e., before starting immunotherapy). The vascular signal fraction  $f_v$  was computed in the initial fitting step, which disentangles the vascular from the non-vascular (tissue) signal, before the latter is split into intra-/extra-cellular contributions in the biophysical model fitting step. The same representation layout as in Fig. S6 was used. Left **(A)**: Kaplan-Meier (KM) analysis, log-rank sum test and Cox regression based on the binarised  $f_v$  (higher/lower than the sample median). Right **(B)**: Cox regression modelling the probability of survival as a continuous function of baseline  $f_v$ . In all panels, the y-axis shows  $1 - p$ , with  $p$  being the probability of progression, while the x-axis shows the time to progression (in days).



**Fig. S16: immunotherapy response assessment based on *Diff-in-exFast* MRI metrics.**

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of all *Diff-in-exFast* metrics within liver tumours at baseline (i.e., before starting immunotherapy). In each row, from top to bottom: PFS based on baseline volume-weighted Cell Size *vCS* (panels A and B), Cell Density *CD* (panels C and D), intra-cellular fraction *F* (panels E

and **F**), intrinsic intra-cellular cytosol diffusivity  $D_{0,I}$  (panels **G** and **H**), asymptotic extra-cellular diffusion coefficient  $D_{E,\infty}$  (panels **I** and **J**). The same representation layout as in Fig. S6 was used. Left (**A**, **C**, **E**, **G**, **I**): Kaplan-Meier (KM) analysis, log-rank sum test and Cox regression based on the binarised MRI metrics (higher/lower than the sample median). Right (**B**, **D**, **F**, **H**, **J**): Cox regression modelling the probability of survival as a continuous function of baseline MRI metrics. In all panels, the y-axis shows  $1 - p$ , with  $p$  being the probability of progression, while the x-axis shows the time to progression (in days).



**Fig. S17: schematic of the dMRI sequences used in this study.**

(A): pulsed gradient spin echo (PGSE sequence, also known as Stejskal-Tanner sequence, pulsed-field gradient (PFG), or single linear diffusion encoding) used to acquire data on the 9.4T Bruker system on fixed mouse livers *ex vivo* and on the 3T GE system on patients *in vivo*.  $\delta$  and  $\Delta$  respectively indicate the diffusion gradient duration and separation, while  $TE$  is the echo time. (B): twice-refocussed diffusion-weighted spin echo sequence used to acquire data on the 1.5T Siemens system on patients *in vivo*.  $\delta_n$  and  $\Delta_{n,m}$  respectively indicate the duration of the  $n$ -th gradient lobe and the separation time between the  $n$ -th and  $m$ -th gradient lobes, for  $n, m = 1, \dots, 4$ .  $TE$  is again the echo time. In both panels, “Signal readout” corresponds to sampling the center of the k-space (i.e., zero spatial frequency).



**Table S1: results of the model selection based on the Total Correlation Score (TCS) as obtained on simulated dMRI signals.**

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals (“Regular fit”: fitting on all b-values with negligible vascular contributions; “High *b* only fit”: fitting on b-values minimising extra-cellular signal contributions). The Table reports the value of  $TCS = r(vCS_{est}, vCS_{gt}) + r(F_{est}, F_{gt})$ , where  $vCS$  is the cell size,  $F$  the intra-cellular fraction,  $r(x, y)$  the Pearson’s correlation between variables  $x$  and  $y$  computed pooling together all synthetic voxels, and where subscripts *est* and *gt* respectively indicate estimated and ground truth values. Higher values of  $TCS$  point towards better model performance. For each protocol and fitting strategy, the model with the highest  $TCS$  is flagged by gray shadowing and bold font.

Model	Protocol: <i>ex vivo</i>		Protocol: <i>in vivo</i> PGSE		Protocol: <i>in vivo</i> TRSE	
	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit
	<i>Diff-in-exTD</i>	0.217	-0.111	0.312	0.202	0.604
<i>Diff-in-ex</i>	0.406	0.089	0.472	0.335	<b>0.700</b>	0.550
<i>Diff-in-exTDFast</i>	0.948	0.827	0.536	0.336	0.618	0.544
<i>Diff-in-exFast</i>	0.952	0.850	0.563	0.349	0.626	0.547
<i>Diff-in</i>	<b>1.222</b>	<b>0.977</b>	<b>0.773</b>	<b>0.462</b>	0.543	<b>0.630</b>

**Table S2: results of the model selection based on the Histology Fidelity Criterion (HFC) as obtained on simulated dMRI signals.**

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals (“Regular fit”: fitting on all b-values with negligible vascular contributions; “High *b* only fit”: fitting on b-values minimising extra-cellular signal contributions). For each model, the table reports the percentage of synthetic voxels where  $HFC = |vCS_{est} - vCS_{gt}|/vCS_{gt} + |F_{est} - F_{gt}|/F_{gt}$  was the lowest across all models. Above,  $vCS$  is the cell size,  $F$  the intra-cellular fraction, and subscripts *est* and *gt* respectively indicate estimated and ground truth values. Higher percentages indicate smaller estimation errors, and therefore point towards better model performance. For each protocol and fitting strategy, the model with the highest proportion of synthetic voxels with minimum HFC is flagged by gray shadowing and bold font.

	Protocol: <i>ex vivo</i>		Protocol: <i>in vivo</i> PGSE		Protocol: <i>in vivo</i> TRSE	
	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit
	<b>Model</b>					
<i>Diff-in-exTD</i>	12.62%	13.56%	21.69%	22.10%	26.69%	20.69%
<i>Diff-in-ex</i>	21.19%	16.62%	<b>25.94%</b>	20.35%	<b>28.94%</b>	24.31%
<i>Diff-in-exTDFast</i>	15.50%	14.94%	10.75%	12.27%	19.69%	14.69%
<i>Diff-in-exFast</i>	21.81%	10.50%	22.25%	11.33%	19.12%	12.12%
<i>Diff-in</i>	<b>28.88%</b>	<b>44.38%</b>	19.38%	<b>33.94%</b>	5.56%	<b>28.19%</b>

**Table S3: results of the model selection based on the Bayesian Information Criterion (BIC) as obtained on simulated dMRI signals.**

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals (“Regular fit”: fitting on all b-values with negligible vascular contributions; “High *b* only fit”: fitting on b-values minimising extra-cellular signal contributions). For each model, the table reports the percentage of synthetic voxels where the Bayesian Information Criterion (BIC, a standard metric of model fitting quality that penalises model complexity) was the lowest across all models. Higher percentages indicate smaller BIC values across synthetic voxels, and therefore point towards better model fitting quality. For each protocol and fitting strategy, the model with the highest proportion of synthetic voxels with minimum HFC is flagged by gray shadowing and bold font.

Model	Protocol: <i>ex vivo</i>		Protocol: <i>in vivo</i> PGSE		Protocol: <i>in vivo</i> TRSE	
	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit	Regular fit	High <i>b</i> only fit
	<i>Diff-in-exTD</i>	0.12%	0.00%	0.00%	0.19%	0.00%
<i>Diff-in-ex</i>	31.25%	15.88%	17.44%	4.69%	<b>40.69%</b>	13.69%
<i>Diff-in-exTDFast</i>	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
<i>Diff-in-exFast</i>	3.44%	0.06%	6.69%	0.00%	21.38%	1.06%
<i>Diff-in</i>	<b>65.19%</b>	<b>84.06%</b>	<b>75.88%</b>	<b>95.12%</b>	38.00%	<b>85.25%</b>

**Table S4: descriptive statistics of histology and MRI metrics in the fixed mouse livers.**

The table reports mean and standard deviation (within brackets) of histology and dMRI metrics in the 7 fixed mouse livers that were scanned on a 9.4T Bruker system. Histological maps were computed within patches matching the in-plane MRI resolution and then warped non-linearly to dMRI space. The histological maps are: per-patch intra-cellular area fraction  $F_{histo}$ , per-patch arithmetic mean cell size  $aCS_{histo}$ ; per-patch volume-weighted mean cell size  $vCS_{histo}$ , cell density per unit patch area  $CD_{histo}$ . dMRI metrics are: apparent diffusion coefficient  $ADC$ , apparent diffusion kurtosis excess  $K$ , intra-cellular signal fraction  $F_{MRI}$ , volume-weighted cell size index  $vCS_{MRI}$ , apparent cell density per unit volume  $CD_{MRI}$ . Metrics  $F_{MRI}$ ,  $vCS_{MRI}$  and  $CD_{MRI}$  are reported for both models *Diff-in-exFast* and model *Diff-in*, with *Diff-in* fitted only to high b-value images ( $b > 1800$  s/mm<sup>2</sup>). In model *Diff-in-exFast*, the extra-cellular ADC does not feature diffusion time dependence and is constrained to be larger than the intra-cellular ADC. In model *Diff-in*, the extra-cellular signal is modelled as negligible compared to the intra-cellular one (i.e., total signal dominated by intra-cellular water). Specimens are: *Control* (normal liver structures); *NA1* and *NA2* (normal appearing cases, i.e., normal liver structures despite sub-cutaneous biopsy implantation); *Pat<sub>infl-3</sub>* (cases developing liver pathology following sub-cutaneous biopsy implantation, consisting of small cell infiltration in sinusoidal spaces, in between larger hepatocytes); *Pat<sub>nec</sub>* (case developing liver pathology following sub-cutaneous biopsy implantation, consisting of necrosis and inflammation).  $aCS_{histo}$ , always considerably lower than  $vCS_{histo}$ , was included to highlight the impact of the largest cells in the computation of statistics based on weighting by cell volume ( $vCS_{histo}$ ).

Specimen	Histology				Standard diffusion metrics		<i>Diff-in-exFast</i> model			<i>Diff-in</i> model at high $b$		
	$F_{histo}$	$aCS_{histo}$ [ $\mu\text{m}$ ]	$vCS_{histo}$ [ $\mu\text{m}$ ]	$CD_{histo}/10^2$ [cell/mm <sup>2</sup> ]	$ADC$ [ $\mu\text{m}^2/\text{ms}$ ]	$K$	$F_{MRI}$	$vCS_{MRI}$ [ $\mu\text{m}$ ]	$CD_{MRI}/10^5$ [cell/mm <sup>3</sup> ]	$F_{MRI}$	$vCS_{MRI}$ [ $\mu\text{m}$ ]	$CD_{MRI}/10^5$ [cell/mm <sup>3</sup> ]
<i>Control</i>	0.75 (0.18)	21.63 (1.85)	27.1 (1.6)	3.2 (1.1)	1.50 (0.32)	0.33 (0.20)	0.60 (0.18)	33.2 (5.7)	0.38 (1.69)	0.56 (0.11)	36.5 (5.1)	0.28 (1.44)
<i>NA1</i>	0.59 (0.25)	23.97 (3.05)	27.8 (3.2)	2.1 (1.1)	1.61 (0.37)	0.10 (0.15)	0.66 (0.25)	30.5 (8.4)	0.69 (2.18)	0.54 (0.16)	32.2 (7.5)	0.45 (1.68)
<i>NA2</i>	0.76 (0.14)	23.46 (1.41)	29.4 (1.2)	2.7 (0.7)	1.43 (0.44)	0.51 (0.29)	0.80 (0.16)	22.2 (4.8)	1.01 (1.35)	0.71 (0.12)	22.8 (5.0)	0.83 (1.15)
<i>Pat<sub>infl1</sub></i>	0.80 (0.20)	15.73 (2.18)	20.8 (2.7)	6.7 (2.2)	0.58 (0.41)	0.98 (0.49)	0.83 (0.13)	13.4 (3.1)	4.20 (2.22)	0.77 (0.14)	12.4 (3.0)	4.86 (2.27)
<i>Pat<sub>infl2</sub></i>	0.79 (0.20)	21.41 (2.29)	26.8 (2.7)	3.5 (1.2)	1.67 (0.39)	0.17 (0.17)	0.37 (0.22)	31.2 (7.5)	0.44 (2.06)	0.41 (0.14)	37.1 (6.0)	0.30 (1.57)
<i>Pat<sub>infl3</sub></i>	0.70 (0.27)	20.95 (1.75)	27.6 (1.7)	3.1 (1.3)	1.57 (0.62)	0.43 (0.31)	0.63 (0.23)	23.6 (8.8)	1.27 (2.62)	0.59 (0.20)	24.2 (8.0)	0.97 (2.01)
<i>Pat<sub>nec</sub></i>	0.52 (0.25)	19.10 (3.33)	25.9 (2.8)	3.4 (2.3)	1.49 (0.44)	0.31 (0.22)	0.61 (0.23)	28.2 (6.6)	0.58 (1.93)	0.54 (0.16)	31.6 (6.7)	0.42 (1.66)

**Table S5. Hazard ratios obtained from Cox regression models controlling for sex, age, and baseline tumour volume.**

The table reports the Hazard Ratios (HR) for different MRI metrics, with relative 95% confidence interval and p-value, estimated through Cox proportional hazard regressions. The models assessed the dependence of the probability of progression on the baseline mean value of MRI metrics within liver tumours, accounting for sex, age and tumour volume. Results are shown for standard diffusion metrics (apparent diffusion and excess kurtosis coefficients,  $ADC$  and  $K$ ), for the vascular signal fraction  $f_v$ , for metrics from model *Diff-in-exFast* (intra-cellular fraction  $F$ , volume-weighted cell size  $vCS$ , cell density per unit volume  $CD$ , intrinsic intra-cellular cytosolic diffusivity  $D_{0,I}$ , extra-cellular asymptotic diffusion coefficient  $D_{E,\infty}$ ) and for metrics from model *Diff-in* (intra-cellular fraction  $F$ , volume-weighted cell size  $vCS$ , cell density per unit volume  $CD$ , intrinsic intra-cellular cytosolic diffusivity  $D_{0,I}$ ) fitted at high b-value ( $b > 900$  s/mm<sup>2</sup>). Grey shadowing highlights HRs whose p-value is  $\leq 0.05$ .

	HR of MRI metric	HR of male sex	HR of age	HR of tumour volume
<b>Standard diffusion MRI metrics</b>				
$ADC$	1.00 (0.67; 1.49); $p = 1.00$	0.71 (0.32; 1.55); $p = 0.39$	0.97 (0.94; 0.99); $p = 0.02$	0.32 (0.06; 1.70); $p = 0.18$
$K$	1.36 (0.94; 1.97); $p = 0.11$	0.64 (0.29; 1.41); $p = 0.27$	0.97 (0.94; 1.00); $p = 0.02$	0.35 (0.08; 1.54); $p = 0.17$
<b>Other metrics (from vascular vs non-vascular fitting initialisation step)</b>				
$f_v$	1.16 (0.79; 1.71); $p = 0.44$	0.77 (0.35; 1.68); $p = 0.51$	0.96 (0.93; 0.99); $p = 0.01$	0.34 (0.17; 2.56); $p = 0.17$
<b>Metrics from MRI model <i>Diff-in-exFast</i></b>				
$F$	0.87 (0.61; 1.26); $p = 0.46$	0.78 (0.35; 1.72); $p = 0.54$	0.97 (0.94; 1.00); $p = 0.02$	0.31 (0.06; 1.58); $p = 0.16$
$vCS$	0.70 (0.44; 1.12); $p = 0.14$	0.78 (0.36; 1.68); $p = 0.53$	0.97 (0.94; 0.99); $p = 0.02$	0.35 (0.08; 1.46); $p = 0.15$
$CD$	1.53 (1.00; 2.34); $p = 0.05$	0.63 (0.29; 1.38); $p = 0.25$	0.96 (0.93; 0.99); $p = 0.01$	0.32 (0.06; 1.81); $p = 0.20$
$D_{0,I}$	1.45 (0.98; 2.14); $p = 0.06$	0.68 (0.31; 1.47); $p = 0.33$	0.96 (0.93; 0.99); $p = 0.01$	0.36 (0.09; 1.35); $p = 0.13$
$D_{E,\infty}$	1.41 (0.97; 2.05); $p = 0.07$	0.69 (0.32; 1.48); $p = 0.34$	0.96 (0.94; 0.99); $p = 0.01$	0.40 (0.13; 1.26); $p = 0.12$
<b>Metrics from MRI model <i>Diff-in</i> fitted to high b-value images</b>				
$F$	0.79 (0.54; 1.17); $p = 0.24$	0.80 (0.36; 1.74); $p = 0.57$	0.97 (0.94; 0.99); $p = 0.02$	0.33 (0.07; 1.49); $p = 0.15$
$vCS$	0.59 (0.37; 0.93); $p = 0.02$	0.66 (0.30; 1.43); $p = 0.29$	0.96 (0.94; 0.99); $p = 0.01$	0.40 (0.12; 1.37); $p = 0.14$
$CD$	1.65 (1.12; 2.44); $p = 0.01$	0.61 (0.28; 1.35); $p = 0.22$	0.96 (0.93; 0.99); $p = 0.01$	0.36 (0.09; 1.52); $p = 0.17$
$D_{0,I}$	1.28 (0.82; 1.98); $p = 0.28$	0.67 (0.31; 1.45); $p = 0.31$	0.96 (0.94; 0.99); $p = 0.01$	0.37 (0.09; 1.48); $p = 0.16$

